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ABSTRACT 
 Title: ESTIMATION OF SERUM BETA CAROTENE IN PATIENTS WITH ORAL SUBMUCOUS FIBROSIS, ORAL SQUAMOUS CELL CARCINOMA 
Background: Oral submucous fibrosis is a chronic, debilitating premalignant condition of the oral mucosa which 
is associated with chewing of areca nut. The etiology and pathogenesis has been studied in detail over the past few 
decades, but many controversies still persist. Increased oxidative stress associated with disturbances in antioxidant 
defense system have been implicated in the pathogenesis of several diseases, most notably oral cancer. 
Aim: To estimate the serum beta carotene level in patients with oral sub mucous fibrosis and oral squamous cell 
carcinoma. 
Materials and Methods: In the present study, totally 180 cases were selected from the Dept. of Oral Medicine 
and Radiology, Tamilnadu Government Dental College & Hospital. They were divided into three groups. Group I 
consisted of 60 patients with clinically diagnosed oral sub mucous fibrosis of different stages. Group II consisted 
of 60 patients with clinically diagnosed and histopathologically proven oral squamous cell carcinoma. Group III 
was the control group which consisted of 60 normal patients. The age of the patients ranged from 20 to 60 years. 
The concentration of Beta Carotene present in the serum samples was determined by Bradley and Hornbeck 
method in Dept. of Biochemistry, Madras Medical College & Hospital. 
Results: Results were analyzed using one way ANOVA test for comparing the concentration of serum beta 
carotene level among group I, II and III. The results of our study revealed a significant decrease in the 
concentration of serum β-carotene level in group II patients (56.46μg/dl) when compared with group I patients 
(77.54 μg/dl) and group III (120.21μg/dl).In group I, patients were compared using clinical staging wherein stage 
II showed the highest serum beta carotene level (79.51 μg/dl) and stage III showed a level of 66.32 μg/dl. But 
when functional staging was compared, stage A had the highest level of serum beta carotene level 82.57 μg/dl, 
while stage C had the lowest level of 53.30μg/dl and stage B in between the two (67.14μg/dl).In group II patients 
were compared based on TNM staging, stage II showed the highest value (72.88μg/dl) and was lowest for stage IV 
(42.31μg/dl). When same patients were compared using histological staging, well differentiated group had the 
highest level of serum β-carotene 58.63μg/dl with lowest level of 34.29μg/dl for poorly differentiated group. 
Conclusion: From the present study, we conclude that oral submucous fibrosis and oral squamous cell carcinoma 
cause a significant reduction in level of serum β-carotene and this decrease correlates well with the disease 
progression. So Beta carotene can be used for the prevention and to limit the progression of these diseases. Further 
longitudinal studies with increased sample size are required to substantiate the role of Beta carotene level in 
precancerous condition and malignancy. 
Keywords: Oral submucous fibrosis, Oral squamous cell carcinoma, antioxidants, β-carotene. 
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                                                    INTRODUCTION 
 
Oxygen is essential for the survival of human life. Yet, paradoxically, Oxygen 
is also involved in toxic reactions and is therefore a constant threat to the well being 
of all living things.  Most of the potentially harmful effects of oxygen are believed to 
be due to formation and activity of reactive oxygen species. The reactive oxygen and 
nitrogen species, mainly free radicals, are found in normal physiological conditions 
and can be beneficial when produced at low levels. At abnormal levels, they are 
known to be involved in the process of development of pre-cancer and cancer. 
 
All forms of life maintain a reducing environment within the cells. The 
maintenance of this status is achieved possibly through the antioxidant defense 
system, which is in action to protect cellular homeostasis against harmful ROS 
(reactive oxygen species) produced during normal cellular metabolism, as well as in 
the pathophysiological states. The antioxidant system is preserved by antioxidant 
substances that maintain the reduced state by a constant input of metabolic energy.
1 
Antioxidant substances are small molecules that can scavenge free radicals by 
accepting or donating an electron to eliminate the unpaired condition. Typically, this 
means that the antioxidant molecule becomes a free radical in the process of 
scavenging a ROS to a more stable and less reactive molecule.  
 
When the endogenous antioxidant defense systems are overwhelmed 
(oxidative stress), the free radicals reach high concentrations, what has been 
implicated in disease states. This paradigm has been widely documented for many 
settings, and a causal relationship has been suggested for oxidative stress and 
pathologic alterations.
2 
6 
 
Oxidative stress is implicated in the causation and progression of different 
diseases including atherosclerosis, carcinogenesis, neuro degenerative diseases, 
chronic inflammatory diseases, radiation damage, ageing and various other patho 
biological effects.
3 
 
Antioxidant molecules can be produced endogenously or provided 
exogenously through diet or antioxidant supplements. Many studies show that dietary 
antioxidants, which include vitamin C (ascorbic acid), vitamin E (α-tocopherol), β-
carotene (a carotenoid), and flavonoids (a subgroup of the phytochemicals), when 
used within experimental in vitro biological systems, act as effective antioxidants 
protecting plasma components and cells from damage. Carotenoids are important as 
they convert into vitamin A when needed and are theorized to have possible 
antioxidant activity.
4
 
 
Beta-carotene is one of literally hundreds of carotenoids found in nature, 
particularly in dark green, deep orange and yellow fruits and vegetables. β-carotene is 
perhaps best known for its role as a precursor to vitamin A, or pro-vitamin A, 
meaning that the human body converts β-carotene to vitamin A as needed. Compared 
to its many carotenoid companions, β-carotene is the most potent source of vitamin 
A.
5 
 
Oral submucous fibrosis (OSMF) is a chronic insidious and progressive 
disease involving oral mucosa. Overall prevalence of this precancerous condition in 
India is about 0.5%, with a range of 0.2-1.2% in different regions of the country.
6 
However, recent epidemiological surveys show an increasing prevalence of this 
malady in different states of India. 
 
7 
 
Oral cancer is a major health concern in many parts of the world. Oral and 
pharyngeal cancer, grouped together, is the sixth most common cancer in the world. 
The annual incidence is about 275,000.
7
 South and South East Asia, including India, 
fall under areas of high incidence rate for oral cancer.
7 
 
In India amongst all malignancies, it is the most common malignancy in males 
and third most common malignancy in females.
8
 Worldwide, oral cancer has one of 
the lowest survival rates and remains unaffected despite recent therapeutic advances.
7
 
For those who develop Oral Squamous cell carcinoma (OSCC), the overall 5-year 
survival rate is approximately 50%, unchanged over the last 30 years.
9
  
 
Oxidants and antioxidants may play a role in the later stages of cancer 
development. There is increased evidence that oxidative process contributes to the 
promotion stages of carcinogenesis, at this stage the level of antioxidants are very 
crucial in prevention and progression of carcinogenesis.
10
 Numerous epidemiological 
studies based on blood measurement and dietary intake (Peto et al 1981, Willett 1990, 
Ziegler 1988) support the hypothesis that high intake of β-carotene may reduce the 
incidence of cancer. 
 
Individuals with oral precancer such as oral submucous fibrosis and oral 
leukoplakia run a risk that is 69 times higher for them to develop oral cancer 
compared to tobacco users who do not have pre cancer.
11
 It has also been reported that 
leukoplakia, an oral premalignant lesion can be successfully treated by antioxidant 
supplementation.
12
 Studies have revealed that serum β-carotene levels were below the 
normal range in all cases of   OSMF    and β-carotene level estimation can be useful to 
monitor the oxidative stress in OSMF.
6,13 
 
8 
 
Oral submucous fibrosis being a premalignant condition and associated with 
carcinogens was thought to have a definite association with reactive oxygen species 
and antioxidant levels which is very crucial in the prevention and progression to oral 
cancer and there is increased evidence that antioxidant vitamin levels may alter 
quantitatively in Oral submucous fibrosis and Oral cancer. 
 
Epidemiological studies have suggested that high endogenous levels of 
prooxidants and deficiencies in antioxidants level are likely to be important risk in the 
progression of pre cancer to cancer.
10
  Free radicals and other reactive oxygen species 
are difficult to measure quantitatively.
14
  Antioxidant nutrients which play a crucial 
role against defense of prooxidants can be measured.  If they are reduced from the 
normal level they can be supplemented.
15
   
 
This clinical study is planned to estimate the serum β-carotene level in Oral 
Submucous fibrosis, Oral Squamous cell carcinoma patients and correlate it with the 
clinical profile and also compare the values with those of healthy individuals. 
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                                                   AIM AND OBJECTIVES 
AIM OF THE STUDY: 
To estimate the serum beta carotene level in patient with Oral sub mucous fibrosis and 
Oral squamous cell carcinoma. 
OBJECTIVES: 
• To analyze the serum beta carotene level between patients with oral sub 
mucous fibrosis and oral squamous cell carcinoma. 
• To compare the serum beta carotene level among different stages of oral sub 
mucous fibrosis. 
• To compare the serum beta carotene level among different stages of oral 
squamous cell carcinoma. 
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REVIEW OF LITERATURE 
  PRECANCEROUS LESION AND CONDITION: 
              Working group of the World Health Organization proposed in 1978 that 
clinical presentations of the oral cavity that are recognized as precancerous (hereafter 
referred to as potentially malignant disorders) be classified into two broad groups, as 
lesions and conditions 
(WHO 1978)
16
, with the following definitions: 
•A precancerous lesion is: a morphologically altered tissue in which oral cancer is 
more likely to occur than in its apparently normal counterpart; 
• A precancerous condition is: a generalized state associated with a significantly 
increased risk of cancer 
Classification of precancerous lesions and conditions [WHO (1978)]
 17 
Precancerous lesions 
 Leukoplakia 
 Erythroplakia 
 Palatal lesions in reverse smokers 
Precancerous conditions 
 Oral Submucous fibrosis 
 Actinic keratosis 
  Lichen planus 
 Discoid lupus erythematosus 
11 
 
POTENTIALLY MALIGNANT DISORDERS: 
                  According to Warnakulasuriya (2007)
18
 the distinction between a 
precancerous lesion and a precancerous condition was considered not just academic. 
At the time these terms were coined, it was considered that the origin of a malignancy 
in the mouth of a patient known to have a precancerous lesion would correspond with 
the site of precancer. On the other hand, in precancerous conditions, cancer may arise 
in any anatomical site of the mouth or pharynx. Therefore he did not favour 
subdividing precancer to lesions and conditions and the consensus view was to refer 
to all clinical presentations that carry a risk of cancer under the term ‘potentially 
malignant disorders’ to reflect their widespread anatomical distribution. 
Oral submucous fibrosis: 
Definition: 
Pindborg J.J. and Sirsat S.M. (1966):
19 
 “Oral submucous fibrosis is an insidious chronic disease affecting any part of the oral 
cavity and sometimes the pharynx. Although occasionally preceded by and/or 
associated with vesicle formation, it is always associated with juxta-epithelial 
inflammatory reaction followed by a fibro-elastic change of the lamina propria with 
epithelial atrophy leading to stiffness of mucosa and causing trismus and inability to 
eat.”  
Historical Review: 
            In ancient Indian Medical Manuscripts, around 400 B.C. Sushruta described a 
condition “Vidari” under the mouth and throat diseases causing progressive narrowing 
of the mouth, depigmentation of oral mucosa and pain on taking food. These are the 
12 
 
typical features of the entity presently known as “oral submucous fibrosis” (cited by 
Mukherjee and Biswas 1972).
20 
            In 1952, Schwartz described 5 Indian women from Kenya with a condition of 
oral mucosa involving the palate and pillars of the fauces to which he ascribed the 
descriptive term “atrophia idiopathica (tropica) mucosae oris.21 
The term “submucous fibrosis of the palate and pillars” was first introduced in 
India by Joshi, an ENT surgeon in 1953.
22 
The first report among non-Indians was 
from Taiwan by Su in 1954.
23 
The wide variation in the terminology of this condition 
is suggestive of the uncertainty regarding the exact etiology, which also reflects on the 
successful management of the case. The term “oral submucous fibrosis” has been 
widely accepted over the years as it implies the nature of the condition in a simplified 
form. 
Incidence and Prevalence: 
OSMF is a chronic oral mucosal condition that occurs predominantly among 
Indians, people of Indian origin living outside India, and occasionally in other 
Asians.
24
 However, sporadic cases have been reported in a female of Caucasian 
descent
25
, a Greek female, and among other Europeans
24
. An ethnic basis has been 
indicated for OSMF because it is found most commonly in Asians
21
.
 
 
 
Schwartz in 1952 first described OSMF in 5 Indian women from Kenya and 
East Africa
26
.Since then numerous reports and studies on OSMF have been published 
in the literature. A sharp spurt in the incidence of OSMF was noted after various areca 
and tobacco products came into the market. 
A survey was conducted by Angadi PV et al (2011)
24
 in a teaching hospital in 
southern India over a period of 16 years, which included 205 cases of OSMF. OSMF 
13 
 
amounted to almost 4.38% of the total cases. It was also observed areca nut/betel nut 
was associated with almost 78% of the patients with OSMF, while smoking alone 
leading to OSMF was seen in a very small percentage of patients (2.43%) and was 
especially associated with beedi smoking. Multiple habits, i.e., areca nut, smoking, 
alcohol was observed in 6.82% people. 
Variations in prevalence figures are common between different studies, 
probably because of difference in clinical criteria for diagnosis. While some authors 
adhered to earlier signs and symptoms such as pain, history of vesicles and ulcers, and 
blanching of mucosa for the diagnosis of OSMF, others looked for fibrous bands as 
the diagnostic criterion
21
.
 
Age: 
           The age of the patients affected in OSMF is highly variable as reported by 
various studies. 
 
Raina C et al (2005)
13 
studied 100 cases of OSMF in Maharashtra, India and 
found that 45% of the patients were in the age group of 21 – 30 years of age. The 
patients ranged from 12 – 78 years, with the mean age of 29.09 years. 
  
An etiological and epidemiological study of OSMF was carried out in Patna, 
Bihar, India by Ahmad MS et al (2006)
27 
including 157 cases of OSMF in the period 
2002 – 2004. Maximum number of cases belonged to 21 – 40 years with the youngest 
recorded case in a 11 year old and oldest one being of 54 years of age.  
 
Hayes ML et al (2006)
28 
reported 2 cases of OSMF in 11 and 13 year old 
patients associated with betel chewing habit.  
14 
 
 
Kumar KK et al (2007)
29 
studied 75 cases of OSMF in Chennai, South India 
and found that half of the study population belonged to the age group of 20 – 29 
years. 
 
Pandya S et al (2009)
30 
in their study on OSMF in Allahabad, India, studied 
239 patients and found that maximum patients were in the 21 – 30 years age group. 
 
A hospital based case-control study conducted by Bathi RJ et al (2009)
31
 
included 220 patients with OSMF. Majority of the patients included were under 35 
years of age (85.5%). 
 
Shirzai M (2011)
32
 reported a case of OSMF in a 15 year old Iranian boy with 
the habit of chewing supari since the age of 10 years about 15 times per day. 
 
A review was done by Angadi PV et al (2011)
24
 on 205 cases in southern 
India diagnosed between January 1989 and June 2005. The age range was 14 - 78 
years, with mean age being 46 years. OSMF was most frequent in the age range of 21 
- 30 years (47.8%). Another interesting finding was that the females affected were at a 
slightly later age range of 3
rd
 -5
th
 decade. 
 
High occurrence of OSMF in the younger age groups has given rise to the 
notion that there will be a parallel increase in the incidence rates of oral cancer in this 
group.
33 
 
 
 
 
15 
 
 
Gender: 
Pindborg JJ et al (1984)
34 
in their study of 89 patients of OSMF in 
Ernakulam, Kerala, India, found 29 males and 60 females with OSMF. 
In 1986, a house-to-house survey of tobacco habits was conducted among 
30,544 villagers of all ages in 373 villages in three areas of Kolar District, Karnataka, 
to gather baseline information for an intervention study. About 8-16% of men and 29-
39% of women had chewing habits. While the content of the substances chewed was 
not defined in this study, a case-control study carried out in Karnataka by one of the 
authors identified the chewing habits as including tobacco, betel leaf, areca nut and 
slaked lime and as being the only tobacco habit of women.
35 
Various reports have suggested an increased female predominance which is in 
accordance with the increased prevalence of the habits in women. The general female 
preponderance may also be related to the deficiency of iron and vitamin B complex 
among many Indian women.
21 
Various investigators have also found a male predominance contradictory to 
the earlier studies. Males were found to be dominating, as they were using gutka and 
other related products more because of easy availability in all the places, whereas 
females being more conscious about their health and esthetic value, probably felt 
uncomfortable to ask the vendors in getting the gutka products. This is one of the 
reasons, which may be responsible for a high male to female ratio.
27 
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Investigator Location 
No. of patients 
studied 
Male: female 
ratio 
Rao ABN (1962)
 Hyderabad 46 17 : 29 
Wahi PN (1966)
 Agra 104 2 : 1 
Pindborg JJ et al (1968)
 India 63 1 : 3 
Shiau YY (1979)
 Taiwan 35 34 : 1 
Caniff JP et al (1986)
 London 
44 (43 Indians + 1 
Pakistani) 
1 : 4.5 
Bailoor DN (1993) Mangalore 12 1 : 1.4 
Maher et al (1994) Pakistan 157 1 : 2.3 
Shah N et al (1998)
 New Delhi 236 1.8 : 1 
Ranganathan K et al (2004) Chennai 185 9.9 : 1 
Raina C (2005)
 Maharashtra 100 3.3 : 1 
Ahmad MS et al (2006) Bihar 157 2.7 : 1 
Kumar KK (2007) Chennai 75 6 : 1 
Pandya S et al (2009)
 Allahabad 239 6.8 : 1 
 
A study was conducted by Seedat et al (1988)
36
 in Durban, South Africa, 
where Indians constituted 46% of the population. Women chewers predominated in 
the ratio of 13:1. Haider SM et al (2000)
37
 found in their study on 325 patients of 
OSMF that 52% were females and 48% were males.  
 
A hospital-based cross-sectional study on various habit patterns associated 
with OSMF was performed in Nagpur, Central India, by Hazarey et al (2007)
38 
over 
a 5-year period. A total of 1,000 OSMF cases were included. The severity of OSMF 
was more prevalent in women than men even though the male: female ratio was 4.9:1. 
They found that, an underprivileged socio-economic status and poor education was 
significantly higher in women than men. These factors may have contributed to the 
increased severity of OSMF in women compared with men. 
 
17 
 
A hospital based case-control study conducted by Bathi RJ et al (2009)
31 
included 220 patients with OSMF. Majority of the patients included were males 
(96.4%). 
 
A review was done by Angadi PV et al (2011)
24
 on 205 cases in southern 
India diagnosed between January 1989 and June 2005. The overall male to female 
ratio was around 11:1 with a general trend towards male preponderance.  
 
             From the literature reviewed, the question “Does gender have any influence 
on oral mucosal disorders among gutka chewers?” seems yet to be answered.39 
However, the recent studies have shown a male predominance. 
 
ORAL CARCINOMA: 
                   Oral carcinoma is a global health problem with increasing prevalence and 
mortality rates. Among these, the majority are squamous cell carcinoma. 
 
Epidemiology: 
                 Oral carcinoma is a global health problem with increasing prevalence and 
mortality rates. It is the sixth most common cancer in the world.
7
 Worldwide, the 
annual incidence exceeds 3,000,000 new cases.
40
 More than 90% of oral malignancies 
are squamous cell carcinomas. There is a wide geographical variation (approximately 
20-fold) in the incidence of this cancer. The areas characterized by high incidence 
rates for oral cancer (excluding lip) are found in the South and Southeast Asia (e.g. 
Sri Lanka, India, Pakistan and Taiwan), parts of  Western (e.g. France) and Eastern 
Europe (e.g. Hungary, Slovakia and Slovenia), parts of Latin America and the 
Caribbean (e.g. Brazil, Uruguay and Puerto Rico) and in Pacific regions (e.g. Papua 
New Guinea and Melanesia).
7
 In high-risk countries such as Sri Lanka, India, 
18 
 
Pakistan and Bangladesh, oral cancer is the most common cancer in men, and may 
contribute up to 25% of all new cases of cancer. 
Age and sex distribution: 
                 In most countries around the world, oral cancer is more common in men 
than in women. The reported sex differences are attributable to heavier indulgence in 
risk habits by men and exposure to sunlight (for lip cancer) as a part of outdoor 
occupations. The ratio of males to females diagnosed with oral cancer, however, has 
declined over the decades and is now about 1.5:1 for the mouth. The risk of 
developing oral cancer increases with age and the majority of cases occur in people 
aged 50 or over. About 6% of oral cancers occur in young people under the age of 45 
years. In high-incidence countries of the world, many cases are reported before the 
age of 40.
7
 
Anatomic sites: 
         Cancer of the buccal mucosa is more common among Asian populations due to 
betel quid/tobacco chewing habits. In Sri Lanka, 40% of oral cavity cancers are found 
on buccal mucosa.
7
 Tongue is the most common site for intraoral cancer among 
European and the US populations, amounting to 40–50% of oral cancers.7 Other 
intraoral sites that can be involved are floor of the mouth, palate and alveolus. 
Oral cancer prevalence in India: 
              Oral cancer constitutes the largest group of malignancies in the Indian 
subcontinent with an incidence rate as high as 30-40%.
41
 Data from National Cancer 
Registry programme of the Indian Council of Medical Research has confirmed the 
fact that oral cancer is indeed a common form of cancer in India.
40
 It is the most 
19 
 
prevalent cancer in males as well as third most common in females.
8
 According to 
Kalyani R et al., among adolescent and young adults, oral cancer was the most 
prevalent cancer in both the genders.
42
 The spectrum of oral malignancy varies from 
place to place within the country with a marked increase in occurrence in many parts 
of the country like Uttar Pradesh, Madhya Pradesh, Gujarat, Bihar and Maharashtra.
7
 
ETIOLOGY AND RISK FACTORS: 
            The aetiology of oral cancer is multifactorial. Based on available global 
evidence, Warnakulasuriya, 2009
7
 grouped the risk factors as established, strongly 
suggestive, possible and speculative factors. 
RISK FACTORS FOR ORAL CANCER AND PRECANCER 
                                              (Warnakulasuriya, 2009
7
 ) 
Established Strongly suggestive Possible Speculative 
Smoking Sunlight (lip) Viruses Mouthwashes 
Chewing tobacco Radiation Immune deficiency Mate drinking 
Snuff dipping   Dentition Periodontal disease 
Alcohol misuse  Ethnicity Familial 
Betel quid, syphilis    
                
 The most important etiological factors are tobacco, excess consumption of 
alcohol 
43 
and betel quid usage, these factors act separately or synergistically.
44
 
Attributable risk of oral
 
cancer due to both tobacco and alcohol is estimated to be 
more than 80%.
7
 A diet deficient in
 
antioxidants is a further factor that predisposes 
towards the development of oral cancer.
45 
Other factors such as HPV infection may 
also be involved.
46 
20 
 
MORBIDITY AND MORTALITY: 
                 Many patients who are successfully treated for oral cancer have to cope 
with the devastating consequences of their treatment. These may affect the patient’s 
appearance and function, e.g. eating, drinking, swallowing and speaking. These 
residual defects may lead to other problems such as depression and nutritional 
deficiency.
7
 
                 For most countries, five-year survival rates for cancers of the tongue, oral 
cavity and oropharynx are around 50%. The best outcome is for the cancer of the lip, 
with over 90% of patients surviving for five year period.
7
 In general, prognosis 
decreases with advanced disease and increasing inaccessibility of the tumour. For 
cancers of both the tongue and the oral cavity, women had higher survival rates than 
men. TNM stage at presentation significantly affects five-year survival. For mobile 
tongue, five-year survival for stage disease is 80%, while for stage 1V survival drops 
to 15%.
7
 
            For most countries age-adjusted death rates from oral cancer have been 
estimated at 3–4 per 100,000 men and 1.5–2.0 per 100,000 for women. 
BETA-CAROTENE: 
 
Beta-carotene is a phytochemical classified as a carotenoid. Although there 
are more than 600 carotenoids found in nature, only about 50 are found in the typical 
human diet. The six most common carotenoids found in human blood are alpha-
carotene, β-carotene, β-cryptoxanthin, lutein, lycopene, and zeaxanthin. Of these, 
alpha-carotene, β-carotene, and β-cryptoxanthin are referred to as provitamin A 
carotenoids.
5 
21 
 
Provitamins are inactive forms of vitamins that the body cannot use until they 
are converted to their active form. Our bodies convert β-carotene to an active form of 
vitamin A, or retinol; thus, beta-carotene is a precursor of retinol.
5 
 
Chemical structure: 
 
Beta-carotene is a fat soluble member of the carotenoids. 
 Much of the natural β-
carotene is composed of “all-trans” isomers.47 
Levin G et al (1997)
48
 have shown that 9-cis β-carotene is a better antioxidant than its 
all-trans counterpart. 
 
 
  
 
 
 
 
 
Units:
49 
One Retinol Activity Equivalent (RAE) (US): 
= 1 μg all-trans-Retinol 
= 2 μg β-carotene in oil 
= 12 μg β-carotene in foods 
= 24 μg β-carotene in foods 
= 24 μg β-cryptoxanthin in foods 
 
C 
O 
H 
Cleavage here results  
in two molecules  
of vitamin A 
Beta carotene 
2 molecules  
of Vitamin A 
(in the form 
of retinol) C 
O 
H 
22 
 
One Retinol Equivalent (RE) (Europe): 
= 1 μg all-trans-retinol 
= 6 μg β-carotene 
= 12 μg other provitamin A carotenoids 
Food sources of β-carotene:5,50 
Fruits         Vegetables 
Apricots      Carrots 
Cantaloupe     Pumpkin 
Mango      Sweet potatoes 
Plantain      Winter squash 
Peaches      Broccoli 
Prunes      Dark green lettuces and spinach 
Watermelon     Red peppers 
 
Recommended dietary intake: 
 
The National Nutrition Societies of Germany, Austria and Switzerland (DACH 2000) 
recommend a daily β-carotene intake of 2-4 mg.49 
 
Mechanism of action: 
 
Two principal mechanisms of action have been proposed for any antioxidant:
51 
1. The first is a chain-breaking mechanism by which the primary antioxidant 
donates an electron to the free radical present in the system.  
2. The second mechanism involves removal of ROS/RNS initiators (secondary 
antioxidants) by quenching chain-initiating catalysts.  
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The antioxidant action of β-carotene is found to be due to the suppression of 
singlet oxygen formation and the reaction with peroxynitrite.
1
 Beta-carotene 
exacerbates DNA oxidative damage and modifies p53-related pathways of cell 
proliferation and apoptosis in cultured cells exposed to tobacco smoke but has no 
significant effect in cells unexposed to tobacco.
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BETA-CAROTENE IN ORAL SUBMUCOUS FIBROSIS AND ORAL 
SQUAMOUS CELL CARCINOMA: 
 
It was probably Bruce Ames who first drew general attention to the 
importance of oxidative damage in human cancer aetiology and the likely importance 
of antioxidant defences.
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A study conducted by Babu S et al (1996)
54
 in 50 patients of OSMF found 
that habitual chewing of pan masala/gutka is associated with earlier presentation of 
OSMF than betelquid use. The absence of the betel leaf and its carotenes such as 
hydroxychavicol was considered to be one of the factors responsible for this 
difference. 
 
Uikey AK et al (2003)
55 
conducted a study to estimate the serum status of 
antioxidants, superoxide dismutase (SOD) and glutathione peroxidase (GPX) in 
OSMF. A total of 60 subjects were included in the study comprising of 30 cases of 
OSMF and 30 healthy controls. In OSMF, serum antioxidant enzyme levels were 
found to be decreased (mean SOD 86.63 ± 20.36 and mean GPX 1.50 ± 0.30 U/ml) 
compared to the control group (mean SOD 127.1 ± 18.14 and mean GPX 2.71 ± 0.43 
U/ml).  
 
The results suggested that low values of SOD and GPX may be associated 
with the development of carcinoma in OSMF. 
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An investigation was undertaken by Subapriya R et al (2003)
56
 to examine 
the blood levels of lipid peroxides and  antioxidants  in oral precancer, preoperative, 
postoperative, and recurrent oral cancer patients, with age- and sex-matched normal 
healthy subjects as controls. In patients with oral precancer and cancer, enhanced lipid 
peroxidation was accompanied by antioxidant depletion. These changes were more 
pronounced in patients with recurrent oral cancer.  
Twelve weeks after surgery, decreased lipid peroxidation was accompanied by 
increased antioxidant levels. The results of this study indicated that the imbalance in 
redox status of oral precancer and cancer patients might be due to enhanced lipid 
peroxidation and compromised antioxidant defences. 
                  
Another clinical follow up study was undertaken on 34 patients by Gupta S et 
al (2004)
6 
to assess the blood levels of lipid peroxidation product - MDA and 
antioxidant defense system in OSMF cases and to re-evaluate the patients after 
antioxidant supplementation. Plasma MDA level was increased in OSMF; β-carotene 
level was found to be decreased in all grades of OSMF cases (81.7+14.3 µg/dl) 
compared to healthy controls (110+20.8 µg/dl), the decrease being more in grade II 
and grade III cases with subsequent increase in the levels on β-carotene 
supplementation. Hence it was concluded that MDA and β-carotene level estimation 
can be useful to monitor the oxidative stress in OSMF cases for better management. 
A cross-sectional study was conducted by Raina C et al (2005)
13
 on 100 
patients with OSMF aged 12-78 years to know the prevalence, predisposing factors 
and clinical profile of OSMF and to estimate serum β-carotene levels in OSMF. Mean 
serum β-carotene levels were 101.8 + 10.7 µg% in controls, 87.7 µg% in grade I, 76.3 
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µg% in grade II, and 69.9 µg% in grade III. Hence, it was concluded that serum β-
carotene levels were below the normal range in all cases of OSMF, but were lower in 
grade II as compared to grade I and lowest in grade III cases.  
Metkari SB et al (2007)
57
 conducted a study on 40 OSMF patients and 40 
controls to correlate the serum levels of lipid peroxidation product MDA, antioxidants 
superoxide dismutase and vitamin A in relation to clinical and histopathological 
grading of OSMF. The mean vitamin A level gradually decreased from clinical grade 
I to grade IV as compared to controls. 
 
Results indicated positive correlation of increased lipid peroxidation and 
decreased antioxidants with clinical grades of OSMF. The study concluded that 
estimation of lipid peroxidation and antioxidants in circulation of OSMF patients 
could help in assessing the degree of oxidative damage of the disease. Further, 
correcting the underlying deficiency of antioxidants could improve the treatment 
planning for OSMF. 
 
‘Antoxid’ is an antioxidant formulation that contains β-carotene, zinc, copper, 
manganese and selenium. It has been found that these micronutrients have antioxidant 
properties and enhance cellular immunity. A study was conducted by Jirge V et al 
(2008)
58  
to evaluate the effects of levamisole and antoxid. Out of 45 patients of 
OSMF, 15 were administered  two capsules of antoxid per day, each day for 6 
consecutive weeks. There was significant improvement in mouth opening and 
reduction in burning sensation.  
 
Another study on 96 cases of head and neck malignancy was conducted by 
Shariff AK et al (2009)
59 
to ascertain the variations in the serum levels of MDA and 
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total antioxidant status in different stages of head and neck malignancies and to 
validate the protective effects of antioxidant supplementation during radiotherapy. 
Pre-treatment serum total antioxidant status was significantly declined in all the stages 
of head and neck malignancies (628.75 ± 76.72 μmoles/L) when compared with the 
values of healthy controls (997.13 ± 82.25 μmoles/L), with increased values after 
radiotherapy and antioxidant supplementation.  
 
The study findings concluded that the estimation of serum MDA and total 
antioxidant status in head and neck malignancy cases served as a good indicator of 
oxidative stress in different stages correlating with the severity and staging of head 
and neck malignancies, also suggesting oral antioxidant supplementation to be an 
adjuvant to radiotherapy.
 
 
Ching S et al (2002)
60 
also observed that increased serum β-carotene levels 
were associated with reduction in breast cancer risk.   
 
Bathi RJ et al (2009)
61
 conducted a study to detect the gene polymorphism of 
detoxification enzymes and estimate the antioxidant enzyme status in patients with 
oral cancer, oral leukoplakia and OSMF. The mean values of glutathione were 
significantly raised in all groups. The mean values of ceruloplasmin and MDA was 
statistically significant among cancer and OSMF patients but was insignificant in 
smokers and cases with leukoplakia.  
They concluded that the level of antioxidant enzymes correlate with the degree 
of oxidative damage. Epidemiological evidence consistently relates low antioxidant 
intake or low blood levels of antioxidants with increased cancer risk. Antioxidant 
levels have thus been used as an indicator for the oxidative stress in such 
conditions.
4,62
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Factors affecting serum β-carotene levels: 
Beta-carotene has been known to be affected by a multitude of factors, 
because of which the serum β-carotene levels in individuals are quite varied. 
 
Metabolic situations in which radicals are formed at a higher rate such as 
stress after an accident, surgery under anesthetic, smoking, alcoholism, handling of 
carcinogens at work, physical exertion, intensive sun exposure etc. greatly reduce the 
concentration of β-carotene in plasma.49 
A study was conducted by Tang G et al (1996)
63 
to investigate the effect of 
gastric acidity on β-carotene using omeprazole. The authors found that serum β-
carotene concentrations were significantly lower at a higher gastric pH of 6.4 + 0.3 
(with omeprazole) than at a gastric pH of 1.3 + 0.1 (without omeprazole). Lipid 
micelles containing carotenoids formed in the duodenum as a result of fat digestion, 
release carotenoids into mucosal cells of the duodenum by passive diffusion, 
determined by the concentration gradients between the two. The authors theorized that 
a higher gastric pH increased the negative surface charges of the carotenoid-
containing micelle and the intestinal lumen, inhibiting passive diffusion. Thus, high 
gastric pH is known to decrease the absorption of beta carotene. 
A study conducted by Berg G et al (1997)
64
 investigated the influence of oral 
contraceptives on the serum concentration of β-carotene. It was concluded that the use 
of oral contraceptives was strongly related to serum β-carotene levels, particularly 
among women above the age of 35 years. This was attributed to the age dependent use 
of oral contraceptives with higher estrogen content (ethylestradiol). 
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Dietary fat is also a factor in carotenoid absorption. High-fat diets (18-24 g fat 
with breakfast, 45 g fat with mid-day meal) produced better β-carotene absorption 
than low-fat diets (no fat for breakfast and 6 g for midday meal) in test meals when 
subjects were given 45 mg β-carotene for five days.65 
 
The association of lifestyle factors including alcohol use, physical activity and 
dietary habits with serum levels of carotenoids (lycopene, lutein, cryptoxanthin and β-
carotene), retinol and α-tocopherol were studied in 194 healthy males aged 24 – 60 
years who smoked more than 15 cigarettes/ day by Kitamura Y et al (1997).
66
 Of the 
dietary items studied, total vegetable intake was significantly, positively associated 
with β-carotene levels, as was fruit intake with serum levels of each carotenoid. 
Alcohol consumption was most strongly and inversely associated with β-carotene.  
 
Another study by Galan P et al (2005)
67 
assessed the relationships between 
energy, nutrient and food intakes, alcohol consumption, smoking status and body 
mass index, and serum concentrations of β-carotene, α-tocopherol, vitamin C, 
selenium and zinc. Women had higher baseline serum β-carotene than men. In 
women, younger age was associated with lowered mean concentration of serum β-
carotene. Alcohol consumers and smokers had lower concentrations of serum β-
carotene. Serum β-carotene concentrations were lower in obese subjects. They 
concluded that serum β-carotene concentrations are primarily influenced by sex, age, 
obesity, tobacco smoking, alcohol consumption and especially dietary intake.  
 
Individuals with higher body mass index are found to have a lower serum β-
carotene concentration. β-carotene is distributed differently between plasma and 
adipose tissue, the former being the dominant storage tissue of β-carotene in humans. 
Accordingly, a person with high fat mass would have a larger proportion of ingested 
29 
 
β-carotene absorbed by fat tissue than would a lean person if all other metabolic 
factors were equal. A second explanation could be that the estimates of β-carotene and 
fibre intakes among obese individuals fail to detect a lower consumption of foods that 
would increase serum β-carotene concentrations.67   
Cigarette smoking, a major risk factor for oropharyngeal cancer, is reported to 
alter oral levels of carotenoids and tocopherols. A study was conducted by Gabriel 
HE et al (2006)
68 
to determine whether chronic smoking is associated with altered 
concentrations of these nutrients in serum and buccal mucosa. It was found that 
chronic cigarette smokers have lower concentrations of many dietary antioxidants in 
serum and buccal mucosal cells compared with non-smokers.  
The lower levels of antioxidants found in smokers may partly be a 
consequence of a greater antioxidant depletion due to a sustained smoke-related 
oxidant load. Components of cigarette smoke in the presence of high oxygen tension 
combine to induce oxidation of the nutrient, resulting in a pro-oxidant effect.
52 
Serum β-carotene is also found to be affected by the levels of triglycerides, 
total cholesterol levels
64 
and cardiovascular drugs
 69,70
 because of which serum β-
carotene has been found to be lower in older individuals.
70 
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MATERIALS AND METHODS 
The study was conducted at 
 Department of Oral Medicine and Radiology, 
            Tamil Nadu Government Dental College and Hospital, 
            Chennai – 600 003. 
 Department of Microbiology, 
             Madras Medical College, 
             Chennai – 600 003. 
The study protocol was approved by the Institutional Ethical Committee. 
DURATION OF THE STUDY: From February 2012 to November 2012. 
SAMPLE DESIGN: 
Totally 180 cases were included under the study. The cases were selected from the 
Department of Oral Medicine and Radiology, Tamil Nadu Government Dental 
College and Hospital, Chennai – 600 003 between February 2012 and November 
2012. All were in the age group of 20 – 60 years. They were divided into three groups 
consisting of 60 cases each.  
 
• Group I (Oral sub mucous fibrosis): Patients with clinically diagnosed oral sub 
mucous fibrosis of different stages- 60 cases. 
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• Group II (Oral squamous cell carcinoma): Patients with clinically different 
TNM staging and   histopathologically proven oral squamous cell carcinoma – 
60 cases. 
• Group III (Control)): Healthy individuals– 60 cases. 
INCLUSION CRITERIA: 
The following patients were included under the study. 
 Age range: 20 – 60 years 
 Gender: Both males and females 
 Group I:  
 Patients with mucosal blanching, burning, hardening and presence of 
characteristic fibrous bands, and decreased mouth opening. 
 None of the lesions should have been treated in any manner prior to 
sample collection. 
 Group II:  
 Patients with clinically different TNM staging and histopathologically 
proven oral squamous cell carcinoma.  
 None of the lesions should have been treated in any manner prior to 
sample collection.  
 Group III:  
 Healthy controls both the gender, age ranges from 20-60 years and free 
of any habits and systemic illness.  
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EXCLUSION CRITERIA: 
 Patients with chronic systemic diseases like diabetes mellitus, 
hypertension, pregnancy, liver disorders and patient under antioxidant 
therapy. 
 Patients not willing to participate in the study. 
METHODOLOGY:  
               Following the selection of cases, written informed consent was obtained 
from all the patients selected for the study. They were requested to sign the 
information sheet after explaining the study procedure. Complete medical history and 
clinical findings of all the cases were recorded in the structured proforma prepared for 
the study. 
 The first appointment included the complete medical history and clinical 
findings of all the cases were recorded in the proforma for the study. Diagnosis of all 
the cases of OSMF was done on clinical grounds (presence of burning sensation, 
restricted mouth opening, mucosal blanching, restricted tongue protrusion and 
presence of palpable fibrous bands). The mouth opening was measured from the 
mesioincisal angle of the maxillary central incisor to mesioincisal angle of mandibular 
central incisor and recorded in mm for dentulous patients. In patients missing 
maxillary and / or mandibular central incisor, the distance between the highest point 
in maxillary and mandibular alveolar crest midline was recorded
71
.  The cases were 
classified into three stages based on mouth opening according to the functional 
staging of OSMF given by Haider SM et al (2000).
37 
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Stage A   : Mouth opening > 20 mm 
Stage B   : Mouth opening = 11-19 mm 
Stage C   : Mouth opening < 10 mm 
   
  The patients were also classified into three stages based on the site of 
involvement according to the clinical staging of OSMF given by Haider SM et al 
(2000).
37  
 
 Stage I: Faucial bands  
 Stage II: Faucial and buccal bands 
 Stage III: Faucial, buccal and labial bands 
 
  Patients with non-healing ulcer/ ulcero-proliferative growth with or without 
Lymphadenopathy (oral cancer).Incisional biopsy is to be performed for clinically 
suspected oral squamous cell carcinoma with different TNM staging and diagnosis to 
be established based on clinical and histopathological findings. Once the clinical 
diagnosis was established, the patients were sent for routine blood investigations. 
Armamentarium: 
Examination of the patient: 
 Electrically operated dental chair  
 Patient’s apron 
 Disposable mouth mask 
 A pair of disposable latex examination gloves 
 Stainless steel kidney trays  
 mouth mirror  
 Stainless steel  probe 
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 Tweezer 
 Divider 
 Metallic scale 
 Tongue depressor 
 
SERUM SAMLPE COLLECTION AND STORAGE: 
 
Collection of serum: 
 A pair of disposable latex surgical gloves (No. 6½) 
 Tourniquet 
 Sterile cotton rolls 
 Surgical spirit (70% ethyl alcohol) 
 5 ml sterile disposable syringe 
 24 gauge needle of 1" length 
 Vaccutainer test tube 
Armamentarium required in Microbiology Department: 
  Sterile glass test-tube 
 Centrifuging machine used at 2500 rpm  
 Automatic pipette with disposable plastic pipette tips  
 Disposable plastic Eppendroff tube 
 Deep freezer 
 
Collection of blood sample: 
• The patient was then asked to attend the next morning after an overnight fast, 
to avoid any dietary influence on the serum beta carotene level. Upon 
returning, the patient was asked to sit comfortably in a dental chair in a 
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reclining position. A tourniquet was then applied above the left cubital fossa, 
and the needle of a disposable 2-ml, 23-gauge syringe was inserted into the 
vein. About 2 ml of venous blood was withdrawn and then transferred to a 
plain 10ml vaccutainer test tube. 
• Then the samples were transferred to the Department of Microbiology, Madras 
Medical College on the same day. There, after the blood had coagulated, the 
test tube containing the blood was subjected to centrifugation for about 4-5 
min at 2500 rpm. The test tube was then removed from the centrifuge, and the 
serum layer was pipetted into a vial. Serum transferred to Eppendroff tube and 
stored at -20 degree. 
Beta-carotene estimation: 
 95% Ethanol 
 Beta-carotene powder 
 Hexane 
 Chemical balance 
 Patient serum 
 100 ml glass beakers (2 in no.)  
 Conical flask 
 Sterile glass test-tubes with a wooden test-tube stand 
 Glass pipettes (2 ml, 10 ml) 
 Cuvette 
 Centrifuging machine used at 2500 rpm  
 Spectrophotometer used at 450 nm 
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Estimation of serum beta-carotene: 
 
       The concentration of Beta Carotene present in the serum samples was determined 
by Bradley and Hornbeck method using a beta-carotene stock standard
72
 (Sigma-
Aldrich Corp. St. Louis, MO, USA). The analysis was performed at the Department of 
Microbiology, Madras Medical College. 
Beta-carotene: 
 Stock β-carotene standard was prepared by dissolving 1 mg of β-carotene in 
10 ml hexane. 
Estimation procedure: 
        The estimation procedure was carried out in dim lighting conditions. Serum (0.2 
ml), 0.2 ml ethanol, and 0.5 ml hexane were pipetted into a small test tube. The 
solvent system was mixed on a vortex mixer 1 min and then centrifuged for 4-5 min at 
2500 rpm. The top hexane layer was carefully removed and recentrifuged in a small 
polyethylene microtube for 2 min in an IEC centrifuge. 
                 A 0.35 ml aliquot was carefully pipetted out and transferred to a 0.4 ml 
Zeiss microcell. Carotene content was determined by reading the solution optical 
density (OD) at 450 nm.  
 
Calculation of concentration of serum Beta Carotene sample: 
          A linear standard curve was generated by plotting the average absorbance of 
each Standard on the vertical axis versus the corresponding Beta Carotene standard 
concentration on the horizontal axis. The amount of Beta Carotene in each sample 
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was determined by extrapolating OD values against Beta Carotene standard 
concentrations using the standard curve. 
 
 
CONCENTRATION OF BETA 
CAROTENE (µg /dl) 
OPTICAL DENSITY 
10 0.014 
25 0.026 
50 0.060 
75 0.090 
100 0.120 
125 0.150 
150 0.184 
175 0.216 
200 0.250 
 
 
BETA CAROTENE STANDARD CURVE 
 
 
 
 
 PHOTOGRAPHS 
 
I-ARMAMENTARIUM 
 
 
FIG 1: DIAGNOSTIC INSTRUMENTS 
 
 
 
 
FIG 2: INSTRUMENTS FOR COLLECTION OF BLOOD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 3: COLLECTION OF BLOOD SAMPLE 
 
 
 
 
FIG 4: CENTRIFUGING MACHINE 
 
 
 
 
FIG 5: TRANSPORTING KIT 
  
 
 
FIG 6: SERUM SAMPLES 
 
FIG 7: DEEP FREEZER 
 
 
 
 
FIG 8: INSTRUMENTS FOR SERUM β-CAROTENE 
 
 
 
 
 
 FIG 9: REAGENTS FOR SERUM BETA CAROTENE ESTIMATION 
 
 
 
 
 
 
 
 
 
 
FIG 10: SPECTROPHOTOMETER 
 
 
 
 
 
 
 
II: CLINICAL CASES 
 
                                      ORAL SUBMUCOUS FIBROSIS 
 
FIG 11: MEASUREMENT OF MOUTH OPENING 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CLINICAL STAGE II 
 
FIG 12: BLANCHING OF THE RIGHT BUCCAL MUCOSA AND 
RETROMOLAR AREA  
 
 
 
 
 
 
 
 
                         
                        
    
  
 
FIG 13: BLANCHING IN SOFT PALATE DEVIATION UVULA TOWARDS 
LEFT SIDE 
                                      
CLINICAL STAGE III 
 
FIGURE 14 
 
       BLANCHING IN LOWER LABIAL MUCOSA                          BLANCHING IN RIGHT BUCCAL 
                                                                                                               MUCOSA AND RETROMOLAR AREA 
 
                 
 
 
 
FIG 15: ORAL SQUAMOUS CELL CARCINOMA (TNM STAGE III, WELL 
DIFFERENTIATED TYPE) 
 
            
 
 
 
FIG 16: ORAL SQUAMOUS CELL CARCINOMA (TNM STAGE IV, 
MODERATELY DIFFERENTIATED TYPE) 
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                                                     MASTER CHART I – GROUP I (ORAL SUBMUCOUS FIBROSIS) 
S.
N
O 
C. 
N
O 
AG
E 
(YE
ARS
) 
S
E
X 
C
H 
S
H 
A
H 
CD ( 
/YEAR
S) 
CF 
(/DA
YS) 
SD 
(/YEA
RS) 
SF 
(/DA
YS) 
AD 
(/YEA
RS) 
AF 
(/MON
THS) 
MOUTH 
OPENING 
(MM) 
Clinical 
staging 
Function
al staging 
Serum beta carotene 
level (microgram/dl) 
1 1 41 M C 0 A 6 4 0 0 10 2 15 II B 69.01 
2 2 53 F C 0 0 30 5 0 0 0 0 24 II A 67.5 
3 3 46 M C S 0 20 4 20 3 0 0 22 II A 76.5 
4 4 45 M C S 0 10 4 20 6 0 0 24 II A 67.32 
5 5 21 M C S A 3 5 3 7 2 2 18 II B 59.01 
6 6 28 M C S 0 5 3 6 6 0 0 26 II A 80.23 
7 7 27 M C 0 0 10 6 0 0 0 0 14 II B 85.01 
8 8 42 F C 0 0 5 3 0 0 0 0 26 II A 72.36 
9 9 30 M C 0 0 7 3 0 0 0 0 21 II A 77.46 
10 10 23 M C S 0 5 4 5 6 0 0 9 III C 58.16 
11 11 22 M C 0 A 3 4 0 0 3 3 27 II A 74.32 
12 12 21 M C 0 0 1 2 0 0 0 0 22 II A 104.4 
13 13 54 M C 0 A 30 5 0 0 30 3 17 II B 68.32 
14 14 32 M C S 0 5 3 4 6 0 0 25 II A 89.39 
15 15 37 M C S A 6 4 3 7 2 2 23 II A 71.37 
16 16 24 M C 0 0 4 3 0 0 0 0 19 II B 65.49 
17 17 32 M C 0 A 7 3 0 0 6 4 21 II A 68.94 
18 18 35 M C 0 0 10 6 0 0 0 0 17 II B 67.11 
19 19 21 M C S 0 4 3 2 3 0 0 29 II A 73.21 
20 20 48 M C 0 A 20 3 0 0 10 2 34 II A 70.04 
21 21 32 M C 0 0 3 4 0 0 0 0 29 II A 92.41 
22 22 27 M C S 0 4 2 4 2 0 0 32 II A 87.32 
23 23 23 M C 0 0 1 2 0 0 0 0 24 III A 112.36 
24 24 37 M C S 0 2 4 10 6 0 0 27 II A 79.64 
25 25 56 M C S A 30 4 30 6 10 3 23 III A 68.82 
26 26 37 M 0 S 0 0 0 12 8 0 0 27 II A 87.14 
27 27 40 F C 0 0 6 4 0 0 0 0 19 II B 73.29 
28 28 22 M C 0 0 4 6 0 0 0 0 27 II A 79.91 
29 29 31 M C 0 A 4 6 0 0 10 2 24 II A 84.62 
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30 30 30 M C 0 0 10 4 0 0 0 0 14 II B 71.42 
31 31 55 F C 0 0 20 4 0 0 0 0 27 II A 76.5 
32 32 50 M C 0 0 35 6 0 0 0 0 22 III A 81.16 
33 33 48 M C 0 A 10 4 0 0 20 3 24 II A 72 
34 34 30 M C 0 0 4 2 0 0 0 0 26 II A 78.13 
35 35 48 F C 0 0 4 3 0 0 0 0 21 II A 100.46 
36 36 37 M C S A 12 6 10 2 10 1 17 III B 54.31 
37 37 60 M C S 0 10 3 40 6 0 0 32 II A 84.61 
38 38 31 F C 0 0 5 4 0 0 0 0 18 II B 73.37 
39 39 55 M C 0 0 30 4 0 0 0 0 36 II A 94.37 
40 40 43 M 0 S 0 0 0 15 6 0 0 29 II A 89.49 
41 41 32 M C 0 A 10 3 0 0 10 1 13 III B 58.39 
42 42 23 M C S 0 6 8 6 7 0 0 9 III C 45.32 
43 43 43 M C 0 0 10 3 0 0 0 0 29 II A 84.89 
44 44 26 M C 0 A 6 4 0 0 6 3 22 II A 93.17 
45 45 59 M C S 0 10 4 30 6 0 0 26 II A 84.01 
46 46 21 M C 0 0 3 6 0 0 0 0 21 II A 95.46 
47 47 28 M C 0 0 6 4 0 0 0 0 27 II A 79.39 
48 48 35 M C 0 0 10 6 0 0 0 0 24 II A 84.14 
49 49 28 M C 0 A 10 6 10 7 8 2 9 III C 57.42 
50 50 30 M C 0 0 4 6 0 0 0 0 26 II A 88.71 
51 51 32 M C 0 A 6 3 0 0 10 3 23 II A 80.36 
52 52 47 M C S 0 12 3 14 6 0 0 32 II A 92.16 
53 53 54 M C S 0 30 6 29 6 0 0 8 II C 52.31 
54 54 30 M C 0 0 4 3 0 0 0 0 31 II A 112.11 
55 55 47 M C 0 0 20 4 0 0 0 0 21 II A 79.26 
56 56 28 M C S 0 4 3 6 3 0 0 27 II A 77.16 
57 57 41 M C 0 0 20 6 0 0 0 0 17 III B 61.01 
58 58 32 M C 0 A 6 4 0 0 6 3 26 II A 73.24 
59 59 30 M C 0 0 40 6 0 0 0 0 33 II A 68.32 
60 60 50 M C S 0 30 3 30 6 0 0 22 II A 79.04 
 
M – Male  F – Female  CH – Chewing Habit  SH – Smoking Habit  AH- Alcohol Habit  CD- Chewing Duration  SD – Smoking Duration  AD- Alcohol 
Duration  CF – Chewing Frequency  SF – Smoking Frequency  AF - Alcohol Frequency 
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                                       MASTER CHART II – GROUP II (ORAL SQUAMOUS CELL CARCINOMA) 
S.No C. 
No 
Age 
(yea
rs)  
S
E
X 
C
H 
S
H 
A
H 
CD ( 
/years
) 
CF 
(/days) 
SD 
(/years
) 
SF 
(/days
) 
AD 
(/years
) 
AF 
(/month
s) 
TNM 
staging  
Histological 
Grading 
Serum Beta Carotene Level 
(microgram/dl) 
61 1 60 M 0 S A 0 0 30 7 20 3 III MD 53.12 
62 2 47 F C 0 0 10 6 0 0 0 0 IV WD 49.39 
63 3 38 M 0 S 0 0 0 15 6 0 0 II WD 96.4 
64 4 59 M 0 S 0 0 0 30 7 0 0 III WD 53.34 
65 5 57 M C S 0 30 3 25 6 0 0 II WD 70.31 
66 6 38 F C 0 0 5 3 0 0 0 0 IV MD 49.17 
67 7 58 F C 0 0 25 6 0 0 0 0 III WD 61.31 
68 8 38 M C S 0 15 3 18 6 0 0 I MD 85.16 
69 9 48 M C S 0 20 4 15 6 0 0 III WD 50.36 
70 10 49 M 0 S 0 0 0 19 7 0 0 II WD 67.6 
71 11 45 F C 0 0 12 3 0 0 0 0 III MD 57.21 
72 12 60 M 0 S 0 0 0 40 6 0 0 III WD 59.32 
73 13 38 M 0 S A 0 0 15 6 15 3 I WD 83.6 
74 14 53 M C S 0 24 4 25 6 0 0 III WD 55.26 
75 15 51 M C S A 20 3 20 6 15 2 III WD 47.24 
76 16 56 F C 0 0 30 6 0 0 0 0 III WD 54.15 
77 17 53 M 0 S A 0 0 30 6 30 3 II WD 58.17 
78 18 57 F C 0 0 24 5 0 0 0 0 III WD 51.32 
79 19 53 M C S 0 30 6 30 7 0 0 IV WD 57.12 
80 20 40 M 0 S 0 0 0 20 6 0 0 II MD 61.2 
81 21 53 F C 0 0 17 6 0 0 0 0 III WD 48.44 
82 22 60 M 0 S A 0 0 40 7 40 2 III WD 49.17 
83 23 48 M 0 S A 0 0 22 6 20 2 IV WD 39.29 
84 24 60 F C 0 0 24 7 0 0 0 0 IV PD 37.16 
85 25 60 M C S A 25 6 30 7 23 2 III WD 51.01 
86 26 59 F C 0 0 20 4 0 0 0 0 IV WD 40.01 
87 27 50 F C 0 0 11 3 0 0 0 0 IV WD 37.16 
88 28 43 M 0 S 0 0 0 20 7 0 0 II WD 59.32 
89 29 42 F C 0 0 6 4 0 0 0 0 III MD 48.16 
90 30 50 M 0 S 0 0 0 20 6 0 0 III WD 53.14 
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91 31 50 F C 0 0 12 3 0 0 0 0 III WD 52.62 
92 32 45 M C S 0 14 4 20 6 0 0 II WD 57.17 
93 33 58 M C S A 20 4 20 6 15 2 I WD 40.17 
94 34 57 M 0 S 0 0 0 30 7 0 0 III WD 89.36 
95 35 50 M 0 S A 0 0 30 6 30 3 IV PD 31.42 
96 36 55 F C 0 0 20 7 0 0 0 0 III WD 57.16 
97 37 32 M 0 S A 0 0 10 6 10 2 III WD 52.12 
98 38 39 M 0 S A 0 0 5 6 10 2 II WD 112.16 
99 39 43 M C S 0 14 3 25 5 0 0 III MD 48.23 
100 40 54 M 0 S 0 0 0 33 6 0 0 I WD 64.15 
101 41 38 M C S A 10 4 10 6 10 1 III MD 45.01 
102 42 59 F C 0 0 31 7 0 0 0 0 III MD 54.11 
103 43 44 F C 0 0 17 4 0 0 0 0 III MD 48.29 
104 44 38 M C S A 10 4 10 3 10 3 III WD 58.31 
105 45 48 F C 0 0 10 4 0 0 0 0 III MD 46.59 
106 46 46 M C S 0 20 6 20 4 0 0 III WD 60.04 
107 47 60 M 0 S 0 0 0 30 6 0 0 IV MD 32.17 
108 48 40 F C 0 0 7 3 0 0 0 0 III WD 55.24 
109 49 57 F C 0 0 35 4 0 0 0 0 II MD 69.41 
110 50 55 F C 0 0 12 3 0 0 0 0 III MD 48.41 
111 51 56 F C 0 0 18 6 0 0 0 0 III MD 51.32 
112 52 47 M C S 0 20 4 20 6 0 0 III WD 66.17 
113 53 40 M C S A 15 6 15 4 15 2 II WD 77.15 
114 54 57 M 0 S A 0 0 35 6 35 3 III WD 61.332 
115 55 55 F C 0 0 13 4 0 0 0 0 IV WD 39.42 
116 56 43 M 0 S A 0 0 21 7 21 3 III WD 52.11 
117 57 37 M 0 S A 0 0 11 5 11 2 III WD 71.39 
118 58 55 M C S A 25 6 25 3 25 3 I WD 44.32 
119 59 39 M C S 0 11 4 12 6 0 0 IV WD 53.14 
120 60 52 M 0 S 0 0 0 30 7 0 0 III WD 65.36 
M – Male  F – Female  CH – Chewing Habit  SH – Smoking Habit  AH- Alcohol Habit  CD- Chewing Duration  SD – Smoking Duration  AD- Alcohol 
Duration  CF – Chewing Frequency  SF – Smoking Frequency  AF - Alcohol Frequency  MD – Moderately Differentiated  WD – Well Differentiated  
   PD – Poorly Differentiated 
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                MASTER CHART III – GROUP III (CONTROL GROUP) 
                                                                                                                                                                                                                   
S.NO. CASE 
NO. 
AGE(Years) SEX Serum Beta Carotene Level (micro 
gram/dl) 
121 1 56 M 119.68 
122 2 51 M 93.52 
123 3 42 M 133.12 
124 4 53 F 97.26 
125 5 33 M 116.26 
126 6 46 F 140.11 
127 7 45 M 133 
128 8 51 F 128 
129 9 27 M 117.12 
130 10 32 M 177.22 
131 11 42 M 99.01 
132 12 31 M 91.46 
133 13 36 F 84.31 
134 14 54 M 113.21 
135 15 53 M 101.23 
136 16 24 M 144.12 
137 17 32 M 126 
138 18 37 M 165.72 
139 19 41 M 88.53 
140 20 33 M 97.12 
141 21 26 M 103.1 
142 22 42 F 117 
143 23 27 M 129.09 
144 24 24 M 121.4 
145 25 55 M 130.9 
146 26 51 M 104.1 
147 27 50 M 111.08 
148 28 28 F 84.71 
149 29 42 M 188.4 
150 30 31 M 143.7 
151 31 33 M 106.16 
152 32 42 M 121.23 
153 33 22 M 142.12 
154 34 57 M 70.31 
155 35 52 F 62.5 
156 36 26 M 223.01 
157 37 42 M 100 
158 38 31 M 97.03 
159 39 55 F 116.12 
160 40 24 M 141.25 
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161 41 26 M 135.11 
162 42 41 M 157.27 
163 43 46 M 142.36 
164 44 32 F 81.01 
165 45 27 M 132.12 
166 46 29 M 114.26 
167 47 37 M 118.16 
168 48 31 M 89.06 
169 49 42 M 99.27 
170 50 44 F 143.21 
171 51 21 M 100.59 
172 52 44 M 101.23 
173 53 36 M 127.12 
174 54 56 M 61.05 
175 55 43 F 136.21 
176 56 29 M 167.11 
177 57 27 M 207.46 
178 58 44 M 90.66 
179 59 34 F 124.12 
180 60 53 M 106.26 
 
M – Male  F – Female 
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STATISTICAL ANALYSIS 
 
      The statistical analysis was done using the computer software program SPSS 
version17. 
 
            The percentage of distribution of various age groups, and of male and female 
were calculated within each study group. The percentage of distribution of various 
clinical staging and functional staging were calculated within the study group I. Also, 
the percentage of distribution of various TNM stages and histological grades were 
calculated within the study group II. 
 
Arithmetic Mean and Standard Deviation were estimated for different 
variables in each study group.  
 
One way ANOVA was used, 
 for comparing the concentration of serum beta carotene level among 
group I, II and III, 
 for comparing the concentration of serum beta carotene level among 
various clinical staging and functional staging  were calculated within 
the study group I, respectively and  
 for comparing the concentration of serum beta carotene level among 
various TNM stages and histological grades were calculated within the 
study group II. 
 
In the present study, P-value <0.05 was considered as the level of significance. 
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TABLES 
 
 
TABLE 1: AGE DISTRIBUTION 
 
 
 
TABLE 2: SEX DISTRIBUTION 
 
Group SEX Total(n) 
(%) Male (n)       
(%) 
Female (n)       
(%) 
 
I 
48 
 
80.0% 
12 
 
20.0% 
60 
 
100.0% 
 
II 
39 
 
65.0% 
21 
 
35.0% 
60 
 
100.0% 
 
 
III 
54 
 
90.0% 
6 
 
10.0% 
60 
 
100.0% 
Total 141 
 
78.3% 
39 
 
21.7% 
180 
 
100% 
 
 
 
 
 
 
 
 
Age 
(years) 
Group TOTAL (n)       
(%) I (n)      
(%) 
II (n)       
(%) 
III (n) 
 (%) 
20-30 23 
 
38.34% 
0 
 
0 
15 
 
25% 
38 
 
21.11% 
31-40 15 
 
25% 
13 
 
21.67% 
15 
 
25% 
43 
 
23.90% 
41-50 14 
 
23.33% 
18 
 
30% 
17 
 
28.33% 
49 
 
27.22% 
51-60 8 
 
13.33% 
29 
 
48.33% 
13 
 
21.67% 
50 
 
27.77% 
Total 60 
 
100% 
60 
 
100% 
60 
 
100% 
180 
 
100% 
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TABLE 3:  COMPARISON OF SERUM β-CAROTENE LEVEL AMONG 
GROUP I, II & III 
 
Group No. of 
patients 
Mean serum β-
carotene level 
(µg/dl) 
Standard 
deviation 
P -value 
I 
 
II 
 
III 
 
60 
 
60 
 
60 
77.54 
 
56.46 
 
120.21 
13.64 
 
14.88 
 
31.74 
 
 
0.000 
P-value – 0.000 i.e. significant at 1% level 
 
 
TABLE 4: COMPARISON OF SERUM β-CAROTENE LEVEL WITH 
CLINICAL STAGING IN GROUP I 
 
Functional Staging 
No. of patients 
(n=60) 
Mean serum  β-
carotene level 
(µg/dl) 
Standard 
deviation 
P-Value  
Stage II 51 79.51 11.38  
0.006 Stage III 9 66.32 19.90 
P-value –0.006 i.e. significant at 1% level 
 
 
TABLE 5: COMPARISON OF SERUM β-CAROTENE LEVEL WITH 
FUNCTIONAL STAGING IN GROUP I 
Functional 
Staging 
No. of patients 
(n=60) 
Mean serum  β-
carotene level 
(µg/dl) 
Standard 
deviation 
p-value  
Stage A  44 82.57 11.15  
0.000 Stage B  12 67.14 8.34 
Stage C 4 53.30 5.92 
P-value – 0.000 i.e. significant at 1% level 
 
 
TABLE 6: COMPARISON OF SERUM β-CAROTENE LEVEL AMONG 
VARIOUS TNM STAGING IN GROUP II 
 
TNM Staging No. of patients 
(n=60) 
Mean serum 
β-carotene 
level (µg/dl) 
Standard 
deviation 
P -value 
I 5 63.48 9.44 0.000 
II 10 72.88 5.71 
III 34 55.16 1.46 
IV 11 42.31 2.57 
P-value – 0.000 i.e. significant at 1% level 
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TABLE 7: COMPARISON OF SERUM β-CAROTENE LEVEL AMONG 
VARIOUS HISTOLOGICAL GRADINGS IN GROUP II 
 
Histological Grading No. of 
patients 
(n=60) 
Mean serum β-
carotene level 
(µg/dl) 
Standard 
deviation 
P -value 
Well differentiated 
 
43 
 
 
58.63 
 
 
15.17 
 
 
0.045 
Moderately 
differentiated 
 
 
15 
 
 
53.17 
 
 
12.06 
Poorly differentiated 
 
 
 
2 
 
34.29 
 
4.06 
P-value – 0.045 i.e. significant at 5% level 
 
 
TABLE 8: DISTRIBUTION OF SERUM β-CAROTENE LEVEL WITH 
CLINICAL STAGING IN GROUP I 
 
Functional Staging 
No. of patients 
(n=60) 
Percentage % 
Stage II 51 85 
Stage III 9 15 
Total 60 100 
 
 
TABLE 9: DISTRIBUTION OF SERUM β-CAROTENE LEVEL WITH 
FUNCTIONAL STAGING IN GROUP I 
 
Functional Staging 
No. of patients 
(n=60) 
Percentage % 
Stage A 44 73.33 
Stage B 12 20.00 
Stage C 4 6.67 
Total 60 100.0 
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TABLE 10: DISTRIBUTION OF VARIOUS TNM STAGING AMONG 
GROUP II 
 
TNM Staging 
 
No. of patients 
(n=60) 
Percentage % 
Stage I 
 
Stage II 
 
Stage III 
 
Stage IV 
5 
 
10 
 
34 
 
11 
8.3 
 
16.7 
 
56.7 
 
18.3 
Total 
 
60 100 
 
 
TABLE 11: DISTRIBUTION OF VARIOUS HISTOLOGICAL GRADES 
AMONG GROUP II 
 
Histological grading 
 
No. of patients 
(n=60) 
Percentage % 
 
Well differentiated 
 
Moderately differentiated 
 
Poorly differentiated 
 
43 
 
15 
 
2 
 
71.67 
 
25.0 
 
3.33 
Total 
 
60 100 
 
 
TABLE 12: COMPARISON OF SERUM β-CAROTENE LEVEL WITH AGE 
IN GROUP I 
 
Age 
(yrs) 
No. of 
patients 
(n=60) 
Mean serum β-
carotene level 
(µg/d)l 
Std. 
Deviation 
P-value 
20-30 23 79.28 17.02  
0.805 31-40 15 75.84 11.01 
41-50 14 78.19 10.79 
51-60 8 74.55 13.11 
P-value – 0.805 i.e. not significant. 
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TABLE 13: COMPARISON OF SERUM β-CAROTENE LEVEL WITH AGE 
IN GROUP II 
 
Age (yrs) No. of 
patients 
(n=60) 
Mean serum β-
carotene level 
(µg/dl) 
Std. 
Deviation 
P-value 
30-40 13 69.23 20.47 0.001 
41-50 18 51.34 9.38 
51-60 29 53.90 11.60 
P-value –0.001 i.e. significant at 1% level 
 
 
TABLE 14: COMPARISON OF SERUM β-CAROTENE LEVEL WITH AGE 
IN GROUP III 
 
Age (yrs) No. of 
patients 
(n=60) 
Mean serum β-
carotene level 
(µg/dl) 
Std. 
Deviatio
n 
P-value 
20-30 15 137.50 37.62 0.015 
31-40 15 116.29 28.84 
41-50 17 123.62 26.75 
51-60 13 100.31 23.22 
P-value –0.015 i.e. significant at 5% level 
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RESULTS 
                This clinical study was conducted among the patients attending the 
Department of Oral Medicine and Radiology, Tamilnadu Government Dental College 
and Hospital. In the present study, totally 180 cases were included. They were divided 
into three groups - I, II and III. Group I consisted of 60 patients with clinically 
diagnosed oral sub mucous fibrosis of different stages. Group II consisted of 60 
patients with clinically diagnosed and histopathologically proven oral squamous cell 
carcinoma. Group III is the control group which consisted of 60. 
               Blood was collected from all the patients and Beta carotene levels were 
estimated by the Bradley and Hornbeck method.
72 
AGE DISTRIBUTION: 
The subjects were divided into four age groups which are as follows: 20-30 
years, 31-40 years, 41-50 years, 51-60 years. Among the 60 in group I, 23(39%) were 
between 20-30 years, 15(25%) between 31-40 and 14(23%) between 41-50 years and 
8(13%) between (51-60) years. The group II comprised of 13(22%) were between  31-
40 years, 18(30%) were between 41-50 years and 29(48%) were between (51-60) 
years. In group III, 15(25%) belonged to 20-30 years, 15(25%) belonged to 31-
40years, 17(28%) belonged to 41-50 years, 13(22%) belonged to 51-60 years.                     
[Table 1, chart 1]. 
 
SEX DISTRIBUTION: 
 
Out of 180 patients included in this study, 141 (78.3%) were males and 39 
(21.7%) were females. In Group I, 48 (80%) were males and 12 (20%) were females. 
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In Group II, 39 (65%) were males and 21(35%) females and in Group III, 54 (90%) 
were males and 6 (10%) were females. [Table 2, chart 2]. 
 
COMPARISON OF SERUM β-CAROTENE LEVEL AMONG GROUP I, II & 
III: 
 
             The mean concentration of serum β-carotene level among groups I, II and III 
were 77.54 µg/dl, 56.46 µg/dl and 120.21 µg/dl respectively. On comparing the 
concentration of serum β-carotene level among groups I, II and III, the results were 
statistically significant between all the three groups (‘p’ value: 0.000 – significant at 
1% level).The mean serum beta carotene level of group II was lower than that of 
group I and group III. The mean serum beta carotene level of group I was lower than 
that of group III. [Table 3, chart 3]. 
 
COMPARISON OF SERUM β-CAROTENE LEVEL WITH CLINICAL 
STAGING IN GROUP I: 
 
           Out of the 60 OSMF patients included in the group I, 51 patients in clinical 
Stage II were found to have a mean serum β-carotene level of 79.51 + 11.38 µg/dl. 9 
patients in Stage III OSMF had a mean serum β-carotene level of 66.32 + 19.90 µg/dl. 
There was a decrease in the mean serum β-carotene level when OSMF progressed 
from clinical Stage II to Stage III. This was found to be statistically significant (‘p’ 
value: 0.006 – significant at 1% level). [Table 4, chart 4]. 
 
COMPARISON OF SERUM β-CAROTENE LEVEL WITH FUNCTIONAL 
STAGING IN GROUP I: 
 
When the mean serum β-carotene levels in different functional stages of OSMF was 
assessed, it was found to decrease progressively with the advancement of functional 
stage. The 44 patients in Stage A had a mean serum β-carotene level of 82.57 + 11.15 
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µg/dl. This was significantly higher than the mean levels in 12 patients in Stage B 
(67.14 + 8.34 µg/dl) and 4 patients in Stage C (53.30 ± 5.92 µg/dl). [Table 5, chart 5]. 
 
         The difference in mean was found to be highly significant statistically between 
Stage A and B, and C, (‘p’ value: 0.000 – significant at 1% level). 
 
        The serum β-carotene level in patients under Group A also correlated with the 
mouth opening using Pearson’s correlation co-efficient. Results showed an r value of 
0.576 and p value of 0.000 which was statistically highly significant. This signifies 
that the serum β-carotene level in patients with OSMF varies directly with regard to 
the mouth opening; i.e. as the mouth opening decreased, the serum β-carotene level 
also decreased simultaneously. Hence, the progression of the disease process was 
associated with further decrease in serum β-carotene level 
. 
COMPARISON OF SERUM β-CAROTENE LEVEL AMONG VARIOUS TNM 
STAGING IN GROUP II: 
 
The mean concentration of serum β-carotene level among stage I, II, III and IV of oral 
squamous cell carcinoma are 63.48 ± 9.44 µg/dl, 72.88 ± 5.71 µg/dl , 55.16 ± 1.46 
µg/dl and 42.31 ± 2.57 µg/dl respectively. The difference in mean was found to be 
highly significant statistically between Stage I and II, III and IV, the p value was 
0.000. [Table 6, chart 6]. 
 
COMPARISON OF SERUM β-CAROTENE LEVEL AMONG VARIOUS 
HISTOLOGICAL GRADINGS IN GROUP II: 
 
The mean concentration of serum β-carotene among well differentiated, 
moderately differentiated and poorly differentiated oral squamous cell carcinoma are 
58.63 ± 15.17 µg/dl,53.17 ± 12.06 µg/dl and 34.29 ± 4.06 µg/dl respectively.When 
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the concentration of serum beta carotene among them were compared, the results 
were significant. (‘p’ value – 0.045) . [Table 7, chart 7]. 
 
DISTRIBUTION OF SERUM β-CAROTENE LEVEL WITH CLINICAL 
STAGING IN GROUP I: 
 
All the three clinical stages were included under Group I (60 cases): Stage II – 
51 cases (85%), Stage III – 9 cases (15%). [Table 8, chart 8]. 
 
DISTRIBUTION OF SERUM β-CAROTENE LEVEL WITH FUNCTIONAL 
STAGING IN GROUP I: 
 
All the three functional stages were included under Group I (60 cases): Stage 
A – 44 cases (73.33%), Stage B – 12cases (20.00%) and Stage C – 4 cases (6.67). 
[Table 9, chart 9]. 
 
DISTRIBUTION OF VARIOUS TNM STAGING AMONG GROUP II 
 
All the four TNM stages were included under Group II (60 cases): Stage I – 5 
cases (8.3%), Stage II – 10 cases (16.7%), Stage III – 34 cases (56.7%) and Stage IV 
– 11 cases (18.3%).[Table 10, chart 10]. 
 
DISTRIBUTION OF VARIOUS HISTOLOGICAL GRADES AMONG GROUP II 
            In the present study, the three different histological grades of oral squamous 
cell carcinoma under group II (60 cases) were distributed as follows: Well 
differentiated squamous cell carcinoma - 43 cases (71.67%), Moderately 
differentiated squamous cell carcinoma – 15 cases (25%) and Poorly differentiated 
squamous cell carcinoma – 2 case (3.33%).[Table 11, chart 11]. 
 
 
61 
 
COMPARISON OF SERUM β-CAROTENE LEVELS WITH AGE IN GROUP I 
In group I subjects, the mean concentration of serum β-carotene level among 
four age groups (20-30, 31-40, 41-50, 51-60) were 79.28µg/dl, 75.84µg/dl ,78.19µg/dl 
and 74.55 µg/dl respectively. On comparing the concentration of serum β-carotene 
level among these age groups, the results were not statistically significant (‘p’ value: 
0.805).[Table 12, chart 12]. 
 
COMPARISON OF SERUM β-CAROTENE LEVEL WITH AGE IN GROUP II 
 
 The mean concentration of serum β-carotene level  among  three  age groups 
(31-40, 41-50, 51-60)  were 69.23 µg/dl , 51.34 µg/dl and 53.90 µg/dl respectively for 
patients with group II situation . But no patients with group II condition belonging to 
age group 20-30 were reported during the study.  On comparing the concentration of 
serum β-carotene level among these age groups, the results were statistically 
significant (‘p’ value : 0.001). The 31-40 age group showed highest mean serum β-
carotene level while 41-50 group had lowest mean serum β-carotene level.[Table 13, 
chart 13]. 
 
COMPARISON OF SERUM β-CAROTENE LEVEL WITH AGE IN GROUP III 
When  serum β-carotene level  were calculated among age groups, (20-30, 31-
40, 41-50, 51-60)  the mean value got were 137.50 µg/dl, 116.29 µg/dl, 123.62 µg/dl, 
100.31 µg/dl respectively. The comparison of these mean values demonstrated a 
statistically significant difference among these four groups (p value: 0.015). The mean 
value was lowest for 51-60 age group, with highest value for 20-30 age group.[Table 
14, chart 14]. 
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DISCUSSION 
Over the last few decades, a new concept involving the biological effects of 
highly reactive oxygen and nitrogen species in the mechanisms causing disease has 
filled the scientific literature. Reactive oxygen species are highly reactive molecules 
and have been implicated in the pathophysiology of many diseases including 
precancerous conditions and cancer. The protective effect in the body against these 
oxygen species is provided by an array of protective antioxidant mechanisms, one of 
which is β-carotene that prevents the production of free radicals and repairs oxidative 
damage. However, when the free radicals are produced in excess, there is a depletion 
of these antioxidants and predisposing the patient to develop disease.
1, 4 
Beta-carotene is known to act in a similar manner and help in maintaining the 
integrity of oral epithelium.  Many studies have shown a decreased serum β-carotene 
in patients with pre-cancerous or cancerous condition. It has been reported that there 
was decreased serum β-carotene level in OSMF patients in many of the previous 
studies.
6,13
Beta-carotene is a micronutrient in the blood whose level seems to be 
affected by a multiple factors like the age, sex, lifestyle, socio-economic status, 
physical activity, smoking, alcohol consumption, gastric pH, dietary intake and body 
mass index.
63,66,67 
Oral submucous fibrosis  has been regarded as a premalignant condition with a 
malignant transformation rate of 7.6% over a period of 17 years.
73
Worldwide 
estimates in 1996 indicate that 2.5 million people were affected by oral submucous 
fibrosis. In 2002, the statistics for OSMF from the Indian continent alone was about 5 
million people (0.5% of the population of India). This indicates that the worldwide 
estimate will be much higher in recent times.
74
The role of the constituents of areca nut 
63 
 
in the pathogenesis of OSMF has been studied in detail over many years. 
Thechemicals in the areca nut appear to interfere with the molecular processes of 
deposition and/or degradation of extracellular matrix molecules such as collagen, 
causing imbalance in the normal process.
75
 
Oral squamous cell cancer has been ranked as the sixth most common cancer 
in the world. It is the most common form of cancer affecting males and account for 
50-70% of all cancer diagnosed in India.
76
Thenumber of patients with oral cancer is 
increasing gradually, especially in younger age group. The purpose of the study was 
to evaluate the level of serum β-carotene in patients with oral submucous fibrosis and 
oral squamous cell carcinoma. 
Total of 180 cases which met inclusive criteria were divided into three groups 
- I, II and III. Group I consisted of 60 patients with clinically diagnosed oral sub 
mucous fibrosis. Group II consisted of 60 patients withclinically diagnosed and 
histopathologically proven oral squamous cell carcinoma. Group III is the control 
group of 60normal people. The age of the patients ranged from 20 to 60 years.The 
concentration of Beta Carotene present in the serum samples was determined by 
Bradley and Hornbeck method using a beta-carotene stock standard
72 
In this study, the serum β-carotene level was decreased in all OSMF patients 
as compared to thehealthy controls and also there was decreased serum β-carotene 
level in patients with oral squamous cell carcinoma as compared to the healthy 
controls. The difference in the serum β-carotene level was highly significant in these 
two comparisons.When compared with OSMF group, patients with Oral Squamous 
cell carcinoma had a significant decrease inserum β-carotene level. (P <0.001). 
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In this study,Group Ipatients within the age range of 20 – 60 years 
wereincluded. More than one third of the study population (38.34%) belonged to the 
age group of 20 – 30 years. As the age advanced, the number of patients with OSMF 
was comparatively fewer. This is in agreement with the studies done by Kumar KK 
et al(2007)
29
, Angadi PV et al (2011)
24
, where a major subgroup of patients were in 
the age range of 21-30 yrs. 
The faster development of OSMF in younger age group may also be attributed 
to the increased mitotic potential of fibroblasts in these patients. In the younger 
people, the fibroblast undergoes approximately 50 cell divisions as compared to the 
older people where the mitotic division is restricted to only about 20
77
. 
Out of 180 patients included in this study, 141 (78.3%) were males and 39 
(21.7%) were females. In Group I, 48 (80%) were males and 12 (20%) were females.     
These gender distributions in this study were consistent with the gender distributions 
found in the study conducted by  Pandya S et al (2009)
30
, Bathi RJ et al (2009)
31
, 
Reddy V et al (2011)
78
 and Angadi PV et al (2011)
24
, who have reported the same 
increased prevalence of OSMF in men. 
Trismus in OSMF occurs due to the increased deposition of collagen fibers in 
the submucosal tissue as the name ‘oral submucous fibrosis’ suggests. This sign is 
characteristically present in all cases of OSMF included in this study and has been 
selected under the diagnostic criteria for OSMF. Mouth-opening has also been used as 
a predictor of the severity and extent of OSMF. Various authors have suggested 
different staging systems based on mouth openingfor OSMF
37, 29, 79
.Functional staging 
by Haider SM et al (2000)
37
were followed to categorizethe patients in this study. 
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Results showed that out of 60 OSMF 44 patients, majority were in functional 
Stage A (73.33%). 12 patients (20.00%) had Stage B OSMF and only 4 patients 
(6.67%) were in Stage C. These findings are in accordance with the study carried out 
in this area of the country by Ceena DE et al (2009)
80
 who found that 72.5% of the 
OSMF patients were in Stage A, 22.5% were in Stage B and only 5% of the cases 
were in Stage C out of 40 OSMF patients. The mild variation in the results can be 
attributed to the varied sample size in both the studies. 
It was observed that a substantial proportion of the patients were in functional 
stage A. The onset of restriction of mouth opening along with burning sensation 
caused inability to eat food and hence was the driving factor for the patients to consult 
the oral medicine specialists for treatment, as bothare thecommon symptoms present 
in the early functional stages of the disease. 
On intra oral examination, all the 60 patients in Group I presented with visible 
blanching and palpable fibrous bands of oral mucosa. This is consistent with the 
findings of other studies on OSMF by Raina C et al (2005)
13
, Haider SM et al 
(2000)
37
,Pandya S et al (2009)
30
 andAngadi PV et al (2011).
24
 
Blanching in OSMF occurs due to impairment of the local vascularity 
subsequent to the deposition of fibrous bands.
81
Palpable fibrous bands of the buccal 
mucosa could be appreciated in all the patients of OSMF in this study, which is in 
accordance with the studies by Ceena DE et al (2006)
73
,Pandya S et al (2009)
30
 
andAngadi PV et al (2011)
24 
who supported the view that buccal mucosa was the 
most frequently affected site.  
Evidence to the contrary was presented by authors like Pindborg JJ et al 
(1964)
82 
and Haider SM et al (2000)
37
who were of the view that faucial pillar is the 
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most commonly affected site. This could be attributed to the swallowing of the 
quid.
83,84 
Though buccal mucosa was the most common site involved in this study as 
evidenced in all 60 OSMF patients, there was no patient in clinical stage I in our study 
and all the patients who had buccal bands also had faucial bands. 9 patients (15%) 
exhibited palpable fibrous bands of labial mucosa as well. This is in accordance with 
the findings of Haider SM et al (2000)
37
who found that all those with buccal bands 
also had bands in the fauces. 
 
It was observed that the fibrous bands were palpated only in the posterior part 
of the buccal mucosa and in faucial pillars in the initial stages of the disease process. 
As the condition advanced, there was involvement of the anterior part of the buccal 
and labial mucosa and in later stages, there was involvement of the floor of the mouth 
and atrophy of the uvula in 2 cases.  
The fibrosis seems to begin around the pterygomandibular raphe causing 
varying degrees of trismus in the patient and then simultaneously progressing to the 
faucial pillars posteriorly and buccal mucosa and labial mucosa anteriorly. This may 
be attributed to the placement of gutka in the buccal vestibule, where the disease 
process is more likely to begin. This is in agreement with the findings of Lemmer J 
et al (1967)
25
, Chiang CP et al (2002)
85
, who stated both buccal mucosa and faucial 
pillars were the most common site. 
As noted in this study, majority of the patients (85%) were in Stage II OSMF, 
with the remaining 15% patients in Stage III. This showed that more than 75% of the 
study population reported for treatment only after the disease had advanced to clinical 
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stage II probably because of the low socioeconomic status and lack of awareness 
about the condition and its implications.  
Supplementation with β-carotene has also been tried by investigators like 
Jirge V et al (2008)
58 
who observed significant improvement in mouth opening and 
reduction in burning sensation after administration of antoxid tablets containing β-
carotene along with other antioxidants. Gupta S et al (2004)found decreased serum 
β-carotene levels in all grades of OSMF cases (81.7+14.3 µg/dl) compared to healthy 
controls (110+20.8 µg/dl), with subsequent increase in the levels on β-carotene 
supplementation. These findings along with the observations in this  study is strongly 
suggestive of increased risk of OSMF in association with low serum β-carotene 
levels.  
 
Beta-carotene is known to be a potent antioxidant. It has been put forth that 
the imbalance in redox status in precancer and cancer might be due to enhanced lipid 
peroxidation and compromised antioxidant defenses.Uikey AK et al (2003)
55
found a 
declined antioxidant level in OSMF patients. Subapriya R et al (2003)
56
supported 
the hypothesis that enhanced lipid peroxidation was accompanied by antioxidant 
depletion in precancer and cancer. As Oral submucous fibrosis and oral squamous cell 
carcinoma has been well recognised, the findings in this  study substantiates the above 
hypothesis.   
 
In this study, the decrease in mean serum β-carotene in OSMF from clinical 
Stage II (79.51 + 11.38 µg/dl) to Stage III (66.32 + 19.90 µg/dl) was found to be 
statistically significant (p = 0.006). Comparison with Stage I could not be carried out 
as there were no patients in this study. This is in accordance with the findings of 
Ashish et al (2011).
86
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The correlation of serum beta-carotene level with the mouth opening showed 
high statistical significance indicating the progression of OSMF with decrease in 
mouth opening.  
 
The subject who had the lowest serum β-carotene level of 45.32 µg/dl seemed 
to have an advanced OSMF condition with a mouth opening of only 9 mm. This also 
suggests that the serum β-carotene level decreases as OSMF progresses. 
 
The results of this study also showed that the mean serum β-carotene level in 
OSMF patients decreased progressively with the advancement from functional stage 
A (82.57+11.15µg/dl) to Stage B (67.14+ 8.34 µg/dl) and further decreased in Stage 
C (53.30 +5.92 µg/dl). This decrease was statistically significant (p < 0.001) among 
three stages. However, the decrease in serum β-carotene level from Stage B to Stage 
C was not statistically significant (p value > 0.05). This could be attributed to the 
small sample size as evidenced by Stage C comprising of only four patients.  
 
The study included 60 patient of oral squamous cell carcinoma. In group II 
patients were in the age range of 20- 60 years. Almost half of the study population 
(48.33%) was found to be in the age group of 51- 60 years. In group III, 28.33% were 
in the age range of 41-50. 
 
In group II 39(65%) were males and 21 (35%) were females. Males were 
found to be more prevalent. In group III 54(90%) were males and 6(10%) were 
females.  
 
In Group II, majority of patient 34(56.7%) were in stage III TNM staging. 
Further there was a significant decrease in the concentration of serum beta carotene 
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among patients with TNM stage II, III, IV with highest mean value for stage II(72.88 
µg/dl) and lowest for stage IV(42.31 µg/dl) (Significant at 1% level). TNM stage I 
(63.48 µg/dl)and stage III (55.16 µg/dl) had serum beta carotene level values in 
between. But there was no significant difference between stage I and stage II. (P value 
is 0.475) This could be due to reduced sample size and other variables such as 
lifestyle, dietary intake, socio economic status, alcohol consumption and smoking 
status.  
 
In the present study 43 (72%) were in well differentiated squamous cell 
carcinoma based on histopathology. Further, we noted a significant decrease in the 
concentration of serum beta carotene among patients with histological grading in the 
advanced stages. Well differentiated had highest mean value of 58.63 µg/dl, poorly 
differentiated showed lowest mean value of 34.29 µg/dl and moderately differentiated  
group had a mean value in between (53.17µg/dl ).There was a significant difference 
among these groups at  5% level.  
An antioxidant
 87
 is a molecule capable of slowing or preventing the oxidation 
of other molecules. Oxidation is a chemical reaction that transfers electrons from a 
substance to an oxidizing agent. Oxidation reactions can produce free radicals, which 
start chain reactions that damage cells. Antioxidants terminate these chain reactions 
by removing free radical intermediates, and inhibit other oxidation reactions by being 
oxidized themselves. As a result, antioxidants are often reducing agents such as thiols, 
ascorbic acid or polyphenols. 
Although oxidation reactions are crucial for life, they can also be damaging; 
hence, plants and animals maintain complex systems of multiple types of 
antioxidants, such as glutathione, vitamin C, and vitamin E as well as enzymes such 
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as catalase, superoxide dismutase and various peroxidases. Low levels of 
antioxidants, or inhibition of the antioxidant enzymes, causes oxidative stress and 
may damage or kill cells. 
As oxidative stress might be an important part of many human diseases, the 
use of antioxidants in pharmacology is intensively studied, particularly as treatments 
for stroke and neurodegenerative diseases. However, it is unknown whether oxidative 
stress is the cause or the consequence of disease. Antioxidants are also widely used as 
ingredients in dietary supplements in the hope of maintaining health and preventing 
diseases such as cancer and coronary heart disease. Epidemiologists studying both 
diet and serum levels of beta-carotene,observed that high levels of beta-carotene, a 
precursor to vitamin A, were associated with a protective effect, reducing the risk of 
cancer. 
The search for treatments that can cause reversal of suppression of pre 
malignancy constitutes an important strategy for overall prevention of cancer.  
Antioxidant micronutrients found in diet have been shown in numerous studies to be 
protective against oral cancer.  There is limited information on the relationship 
between blood antioxidant micronutrient levels and pre cancer, oral cancer.   
Carotenoids are natural compounds with lipophilic properties, greater than 500 
different compounds have been identified and β-carotene is the most prominent 
among them. β-carotene contains an extended system of conjugated double bonds 
which is responsible for its antioxidant activity.  Epidemiological studies in humans 
have suggested that β-carotene aids in cancer prevention.  β-carotene also helps to 
reverse the field cancerization defect in the epithelium at risk for oral cancer.
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β-carotene suppresses micronuclei in exfoliated oral mucosal cells for subjects 
at risk for Oral cancer.  Studies showed that regular intake of β-carotene considerably 
decreases the risk of malignant transformation of oral premalignant conditions and 
lesions.
88-92 
The control group was selected with the inclusion of individuals without any 
systemic diseases because wide range of systemic disease is thought to contribute to 
the development of oxidative stress. The antioxidant levels will be reduced during 
oxidative stress, the systemic diseases include Alzheimer’s disease as stated by 
Christen (2000)
93, Parkinson’s disease as stated by Wood et al (2006)94, diabetes as 
stated by Davi et al (2005)
95
, motor neuron diseases as stated by Cookson (1999)
96
, 
cardiovascular disease as stated by Aviram (2000)
97
and general tissue damage as 
stated by Rhee (2006)
98
. 
Serge Hereberg in 2005
99
stated that a combination of antioxidants including 
β-carotene, vitamin C & vitamin E, at doses achievable through the diet, may have 
protective effects on mortality rates and on the total number of cancers among 
apparently healthy men, with no evident increase in cancer risk.  
The analysis of thisstudy suggested that the level of β-carotene decreased 
asprecancerous and cancerous conditionsprogress into the advanced stages and its 
estimation can be useful to monitor the oxidative stress in these cases for better 
management. Increased dietary intake of beta carotene can probably provide a 
productive effect against OSMF and prevent further progress into cancer. 
Also,pharmacological supplementation of β carotene can be tried as a treatment 
modality in subjects who have already developed precancerous and cancerous 
conditions. 
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SUMMARY AND CONCLUSION 
In the present study, totally 180 cases were included. They were divided into 
three groups - I, II and III. Group I consisted of 60 patients with clinically diagnosed 
oral sub mucous fibrosis of different stages. Group II consisted of 60 patients 
withclinically diagnosed and histopathologically proven oral squamous cell 
carcinoma. Group III is the control group which consisted of 60.The age of the 
patients ranged from 20 to 60 years. Both male and female were included under the 
study. None of the lesions were treated in any manner prior to sample collection. 
Informed consent was obtained from all the patients prior to the investigation. 
Thorough clinical examination was done.Biopsy was performed for all the cases of 
oral squamous cell carcinoma diagnosis were established based on clinical and 
histopathological findings.All the findings were recorded on the structured proforma.  
The Blood samples were collected and all samples were centrifuged and serum 
samples wereseparated. Then the serum samples were frozen at -20 degree Celsius 
until analysis.  The concentration of Beta Carotene present in the serum samples was 
determined byBradley and Hornbeck method.
72 
The results of our study revealed a significant decrease in the concentration of 
serum β-carotene in oral squamous cell carcinoma patients than oral submucous 
fibrosis patients and healthy controls. Also, a significant decrease in concentration of 
serum β-carotene was noted in oral submucous fibrosis patients as compared with 
healthy controls but it was significantly higher when compared with oral squamous 
cell carcinoma patients. Oral submucous fibrosis was more commonly observed in 
younger age group of 20-30 years. It affected the males more predominantly. Majority 
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of the patients belonged to clinical stage II and functional stage A.  In addition to this, 
a significant decrease in concentration of serum β-carotene was noted between TNM 
stage II and stage III, stage IV & different histological grading of oral squamous cell 
carcinoma. 
From the present study, we conclude that Beta carotene plays an important 
role in pathogenesis of oral submucous fibrosis and oral squamous cell carcinoma, 
and that its level decreases with disease progression. These study findings suggest that 
a significant increase in the oxidative stress with concomitant decrease in the 
antioxidant enzymes in OSMF, OSCC patients. There is increased production of ROS 
by cancer cells and also suppression of antioxidant system.This oxidant–
antioxidantimbalance is thought to be one of the factorswhich may be responsible for 
carcinogenesis and tumorgrowth and invasion. Thus maintenance of balancebetween 
the oxidant and antioxidants by appropriatetherapy may be of some help to limit the 
progression ofprecancerous condition towards malignancy. Further longitudinal 
studies with increased sample size are required to substantiate the role of Beta 
carotene level in precancerous condition and malignancy. 
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STUDY PROFOMA 
ESTIMATION OF SERUM BETA CAROTENE IN PATIENTS WITH ORAL SUB 
MUCOUS FIBROSIS, ORAL SQUAMOUS CELL CARCINOMA  
Date:                                                                            Serial no: 
Name:                                                                          O.P No: 
Age/Sex: 
Address: 
 
Phone no: 
Occupation:                                                                Income: 
Religion: 
Presenting complaint with duration: 
 
 
Past medical history: 
 
Past Surgical history: 
 
Past dental history: 
 
 
Personal history: 
A) Diet: 
 
B) Teeth cleaning habits: 
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 Cleaning aids used: 
 Frequency              : 
 
C) Smoking habit: 
 Material used: 
 Frequency      : 
 Duration of the habit: 
 
D) Chewing habit: 
 Material used: 
 Frequency      : 
 Duration of the habit: 
 
E) Other habits (alcohol, snuff): 
 
Marital status: 
 
 
 
Family history: 
 
 
 
CLINICAL EXAMINATION 
General examination: 
 Appearance: 
 
 Build and stature: 
 
 Nutritional status: 
 
 Any deformity: 
 
 Temperature: 
 
 Pulse: 
 
 Blood pressure: 
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 Height & weight: 
 
 Body Mass Index: 
 
 Icterus: Present / Absent 
 
 Clubbing of fingers: Present / Absent 
 
 Cyanosis: Present / absent 
 
 Lymph Node Examination: 
 
Local examination: 
Extraoral examination: 
 On Inspection: 
 
 
 
 
 On Palpation: 
 
 
 
Intraoral examination: 
 Mouth opening (Inter incisal distance): 
 
 
 
 Teeth: 
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 Gingiva and alveolar mucosa: 
 
 
 
 
 Labial and buccal mucosa: 
 
 
 Hard and soft palate, Uvula: 
 
 
 Tongue: 
 
 
 Floor of the mouth: 
 
 
 
 Retromolar trigone: 
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Clinical diagnosis: 
          
 
 
Investigations: 
 
1) Laboratory investigations: 
 
A) Blood: 
Total WBC count:                                          Erythrocyte 
sedimentation rate: 
Differential count:                                        Bleeding time: 
Haemoglobin %:                                             Clotting time: 
Peripheral smear: 
 
 
B) Urine: 
Glucose: 
Albumin: 
 
2) Radiological Examination: 
 
 
 
 
3) Histological analysis: 
 
 
 
 
 
 
Final diagnosis: 
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                  INFORMED CONSENT FORM  
 
STUDY TITLE: 
 
ESTIMATION OF SERUM BETA CAROTENE IN PATIENTS WITH ORAL SUB 
MUCOUS FIBROSIS, ORAL SQUAMOUS CELL CARCINOMA AND HEALTHY 
CONTROLS 
 
Name:        O.P.No: 
 
Address:               Serial No: 
 
               Age / Sex:  
Tel. no: 
 
I, ___________________________________________________age____years 
Exercising my free power of choice, hereby give my consent to be included as a 
participant in the study “ESTIMATION OF SERUM BETA CAROTENE IN 
PATIENTS WITH ORAL SUB MUCOUS FIBROSIS, ORAL SQUAMOUS CELL 
CARCINOMA AND HEALTHY CONTROLS”. 
 
 I agree to the following: 
  
 I have been informed to my satisfaction about the purpose of the study and 
study procedures including investigations to monitor and safeguard my body 
function. 
 I agree to use my serum sample for the study. 
 I agree to cooperate fully and to inform my doctor immediately if I suffer any 
unusual symptom. 
 I have informed the doctor about all medications I have taken in the recent 
past and those I am currently taking and other systemic illness that I have. 
 I agree to report to the doctor for a regular follow-up as and when required for 
the research. 
 I hereby give permission to use my medical records for research purpose. I 
am told that the investigating doctor and institution will keep my identity 
confidential. 
 
 
 
Name of the patient               Signature / Thumb impression  
 
 
Name of the investigator   Signature   Date 
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                                                      INFORMATION SHEET 
 
 We are conducting a study on estimation of serum beta carotene 
level in patients with oral sub mucous fibrosis, Oral squamous cell 
carcinoma and healthy controls. For that study, we are selecting 
patients. 
 The purpose of this study is to estimate the level of serum beta 
carotene level in patients with oral sub mucous fibrosis, Oral 
squamous cell carcinoma and healthy controls. 
 The identity of the patients participating in the research will be 
kept confidential throughout the study. In the event of any 
publication or presentation resulting from the research, no 
personally identifiable information will be shared. 
 Taking part in the study is voluntary. You are free to decide 
whether to participate in the study or to withdraw at any time; your 
decision will not result in any loss of benefits to which you are 
otherwise entitled. 
 The results of the special study may be intimated to you at the end 
of the study period or during the study if anything is found 
abnormal which may aid in the management or treatment. 
 
 
 
Name of the patient        Signature / Thumb impression
  
 
 
 
 
Name of the investigator              Signature 
 
Date:  
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DECLARATION 
 
TITLE OF DISSERTATION “ESTIMATION OF SERUM BETA CAROTENE 
IN PATIENTS WITH ORAL SUB MUCOUS 
FIBROSIS, ORAL SQUAMOUS CELL 
CARCINOMA” 
PLACE OF STUDY Department of Oral Medicine and Radiology, 
Tamil Nadu Government Dental College and 
Hospital, Chennai-600003 and Department of 
Biochemistry ,Madras Medical College,Chennai-
600003 
 
DURATION OF THE COURSE 3 Years 
NAME OF THE GUIDE DR.S.Jayachandran M.D.S, Ph.D 
HEAD OF THE DEPARTMENT DR.S.Jayachandran M.D.S, Ph.D 
 
I hereby declare that no part of the dissertation will be utilized for gaining 
financial assistance/any promotion without obtaining prior permission of the 
Principal, Tamil Nadu Government Dental College and Hospital, Chennai-600003. In 
addition, I declare that no part of this work will be published either in print or in 
electronic media without the guide who has been actively involved in dissertation. 
The author has the right to reserve for publish of work solely with the prior 
permission of the Principal and Guide, Tamil Nadu Government Dental College & 
Hospital, Chennai-600003.  
 
Guide and Head of the Department   Signature of the candidate 
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                                         TRIPARTITE AGREEMENT 
This agreement herein after the “Agreement” is entered into on this day 
…………….between the Tamil Nadu Government Dental College and Hospital 
represented by its Principal having address at Tamil Nadu Government Dental 
College and Hospital, Chennai - 600 003, (hereafter referred to as, ’the college’) 
                                                      And 
Dr. S. Jayachandran, aged.49 years working as Professor & HOD in Department of 
Oral Medicine and Radiology at the college, having residence address at A.M 16, 
TNHB Quarters, Todhunter Nagar, Saidapet, Chennai – 600 015 (herein after referred 
to as the ‘Principal Investigator’) 
                                                       And 
Dr. P.Vijayachandar aged 26 years currently studying as Post Graduate student in 
Department of Oral Medicine and Radiology, Tamilnadu Government Dental College 
and Hospital, Chennai - 3 (herein after referred to as the ‘PG student and co- 
investigator’). 
Whereas the PG student as part of his curriculum undertakes to research on 
“ESTIMATION OF SERUM BETA CAROTENE IN PATIENTS WITH ORAL 
SUB MUCOUS FIBROSIS, ORAL SQUAMOUS CELL CARCINOMA” for 
which purpose the Principal Investigator shall act as principal investigator and the 
college shall provide the requisite infrastructure based on availability and also provide 
facility to the PG student as to the extent possible as a Co-investigator. 
Whereas the parties, by this agreement have mutually agreed to the various issues 
including in particular the copyright and confidentiality issues that arise in this regard. 
Now this agreement witnessed as follows 
1. The parties agree that all the Research material and ownership therein shall 
become the vested right of the college, including in particular all the copyright 
in the literature including the study, research and all other related papers. 
2. To the extent that the college has legal right to do go, shall grant to licence or 
assign the copyright so vested with it for medical and/or commercial usage of 
interested persons/entities subject to a reasonable terms/conditions including 
royalty as deemed by the college. 
3. The royalty so received by the college shall be shared equally by all the three 
parties. 
4. The PG student and Principal Investigator shall under no circumstances deal 
with the copyright, Confidential information and know – how - generated 
during the course of research/study in any manner whatsoever, while shall sole 
west with the college. 
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The PG student and Principal Investigator undertake not to divulge (or) cause to 
be divulged any of the confidential information or, know-how to anyone in any 
manner whatsoever and for any purpose without the express written consent of the 
college. 
5. All expenses pertaining to the research shall be decided upon by the Principal 
Investigator/Co-investigator or borne sole by the PG student.(co-investigator) 
6. The college shall provide all infrastructure and access facilities within and in 
other institutes to the extent possible. This includes patient interactions, 
introductory letters, recommendation letters and such other acts required in 
this regard. 
7. The Principal Investigator shall suitably guide the Student Research right from 
selection of the Research Topic and Area till its completion. However the 
selection and conduct of research, topic and area of research by the student 
researcher under guidance from the Principal Investigator shall be subject to 
the prior approval, recommendations and comments of the Ethical Committee 
of the College constituted for this purpose. 
8. It is agreed that as regards other aspects not covered under this agreement, but 
which pertain to the research undertaken by the PG student, under guidance 
from the Principal Investigator, the decision of the college shall be binding 
and final. 
9. If any dispute arises as to the matters related or connected to this agreement 
herein, it shall be referred to arbitration in accordance with the provisions of 
the Arbitration and Conciliation Act, 1996. 
  
In witness whereof the parties hereinabove mentioned have on this the day 
month and year herein above mentioned set their hands to this agreement in 
the presence of the following two witnesses. 
 
 
 
  
   College represented by its Principal                                 PG Student  
 
 
 
  
 
Witnesses                                                                         Student Guide 
  1.  
 
 2. 
